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Binary therapeutic approaches, in which two low-toxicity components are only activated when 
combined and co-localized in tumors, are a promising strategy to reduce morbidity and improve 
mortality. One of such approaches is Boron Neutron Capture Therapy (BNCT). In this 
therapeutic modality, high levels of boron atoms are accumulated in tumors, which are 
subsequently irradiated with thermal neutrons to trigger cellular damage via the 10B(n, α, γ)7Li 
nuclear reaction. To date, two compounds have been tested in clinical practice showing 
promising results, but with limitations and only in specific tumor types.   
The successful application of BNCT has been thwarted by a number of problems, not least the 
unease around conducting clinical irradiations in nuclear research reactors. This drawback has 
been recently mitigated by the installation of hospital-based accelerators delivering high intensity 
epithermal neutron beams. Apart from this, the main limitation of BNCT is the need to develop 
drugs that are able to deposit a sufficient number of 10B atoms specifically (or preferentially) in 
tumor cells or tissues. Abnormal metabolism and the over-expression of certain membrane 
receptors have previously been exploited to accumulate 10B nuclei in cancer cells. Small boron 
molecules have been used to prepare carbohydrate, amino acid, peptide, and nucleic acid 
derivatives and immunoconjugates, although results have been far from optimal. 
The recent emergence of nanotechnologies has opened new avenues for the development of 
nanomaterial-based boron carriers. Nanomaterials have the advantage that, when appropriately 
designed, have a long circulating half-life and preferentially accumulate in cancer tissues due to 
the enhanced permeability and retention (EPR) effect. In the current PhD thesis, we have worked 
on the development of gold-nanomaterial based boron carriers with potential application in 
BNCT. 
First, we synthesized and characterized spherical gold nanoparticles (AuNPs) with a core 
diameter of ca. 20 nm. The AuNPs were functionalized simultaneously with poly(ethylene)glycol 
(PEG) and the boron rich anion cobalt-bis(dicarbollide), commonly known as COSAN. 
Radiolabeling of the NPs both at the core and the shell was achieved by using the positron 




biodistribution of the AuNPs was monitored in a mouse tumor model, generated by subcutaneous 
inoculation of HT 1080 cells. PET images revealed high accumulation of the radioactivity in the 
liver at short times after administration, suggesting sequestration of the NPs by the mononuclear 
phagocytic system and consequent low bioavailability, which resulted in low tumor 
accumulation. Comparison of the results obtained with the NPs labeled both at the core and the 
shell confirmed good stability of the NPs in vivo. These results are included in Chapter 3. 
The results obtained in chapter 3 suggested the need for the modification of the characteristics of 
the NPs, in order to prolong circulation time and enhance tumor accumulation. Hence, we 
synthesized and characterized smaller NPs with a similar surface functionalization. With that 
aim, NPs with core sizes of ca. 3 and 10 nm and functionalized with PEG and COSAN were 
prepared and characterized using different techniques. The NPs showed low toxicity and good 
internalization properties in cells. Radiolabeling to enable in vivo imaging was achieved by 
incorporation of the positron emitter copper-64 into the gold core. Biodistribution studies 
confirmed that medium sized NPs (core size of ca. 10 nm) rapidly accumulated in the liver and 
showed low accumulation in the tumor. However, the smallest NPs, with a cores size of ca. 3 nm, 
showed long circulation time, lower accumulation in the liver and higher accumulation in the 
tumor, with maximum values at t = 24 hours (5.3±1.3 %ID/cm3). These values progressively 
decreased afterwards (3.92±1.7 %ID/cm3 at t = 48 hours). Additionally, good tumor 
discrimination could be observed on the PET images.   
In spite of the improvement in tumor accumulation obtained in chapter 4, the concentration of 
boron in the tumor was insufficient to tackle therapeutic efficacy experiments. Hence, the next 
step was to design therapeutic agents enabling the combination of BNCT with another 
therapeutic modality. Taking advantage of the capacity of gold nanorods to interact with infrared 
light to generate local heating, we decided to prepare gold nanorods simultaneously 
functionalized with PEG and COSAN, in order to enable simultaneous or sequential BNCT and 
photothermal therapy. The resulting GNRs showed good internalization capacity in MKN45 cells 
and low toxicity both in MKN45 and human dermal fibroblasts (HDFa). Treatment of the GNRs 
with 64CuCl2 in the presence of a reducing agent enabled the incorporation of the positron emitter 
at the gold core, resulting in stable labeling in different media. In vivo biodistribution 
experiments in a xenograft mouse model generated by inoculation of MKN45 cells demonstrated 




administration. Such multidecorated GNRs carry large amounts of boron, and hence bear the 
potential to become a valuable tool for the development of nanoparticle-based BNCT agents. 
This, together with the capability to absorb near infrared light, opens new avenues for their use in 







A pesar de los avances recientes, el cáncer sigue siendo un problema urgente de salud pública. 
Los avances en el diagnóstico temprano y el tratamiento del cáncer han elevado la tasa de 
supervivencia a 5 años para todos los cánceres del 50% (1974) al 68% (2007). Sin embargo, el 
cáncer todavía representó 8.2 millones de muertes en todo el mundo en 2012. Por lo tanto, se 
requiere con urgencia el desarrollo de nuevos tratamientos y terapias, pero dado que muchas 
terapias resultan altamente tóxicas para los pacientes, la eficacia terapéutica debe equilibrarse con 
los efectos secundarios y tóxicos derivados de la propia terapia.  
Los enfoques binarios para la terapia contra el cáncer, en los que dos componentes del 
tratamiento de forma individual presentan baja toxicidad pero al combinarse presentan efecto 
terapéutico, son estrategias prometedoras para mejorar los resultados terapéuticos y reducir los 
efectos secundarios.  
Una opción es la terapia de captura de neutrones de boro (BNCT). Esta terapia se basa en la alta 
propensión del boro-10 (10B) a capturar neutrones térmicos, lo que da como resultado la reacción 
nuclear 10B(n, α, γ)7Li. Las partículas alfa y los iones de 7Li presentan una transferencia de 
energía lineal muy elevada, y alcances en el rango del diámetro de una sola célula. Por lo tanto, si 
se acumula una cantidad suficiente de 10B de manera selectiva o preferente en las células 
tumorales y posteriormente se irradia la zona tumoral con neutrones, es posible generar daño 
selectivo en el tumor, con afectación mínima del tejido sano circundante (Figura 1).  
La aplicación de la BNCT se ha visto limitada por una serie de problemas, entre ellos la 
inconveniencia de requerir una fuente de neutrones, lo que obligaba a realizar las pruebas en las 
inmediaciones de un reactor nuclear. Sin embargo, este inconveniente ha sido mitigado 
recientemente por la instalación de aceleradores hospitalarios capaces de generar haces de 
neutrones de alta intensidad. La segunda limitación se debe a la necesidad de desarrollar 
fármacos que puedan depositar un número suficiente de átomos de 10B específicamente (o 
preferentemente) en células o tejidos tumorales. Históricamente, se han explotado el metabolismo 
acelerado y la sobreexpresión de ciertos receptores de membrana que tienen lugar en las células 




tumor, si bien los resultados no han sido muy prometedores y en la actualidad sólo hay dos 
compuestos que se utilizan en el entorno clínico. Además, éstos muestran poca especificidad y su 
aplicación se limita a un número restringido de tumores.  
Célula sana
Célula cancerígena
Molécula rica en 10B
Ion Li/partícula alfa
 
Figura 1. Esquema del principio de la BNCT. Si se acumula una cantidad suficiente de 10B de manera 
selectiva o preferente en las células tumorales y posteriormente se irradia la zona tumoral con neutrones, 
es posible generar daño selectivo en el tumor, con afectación mínima del tejido sano circundante.  
Los avances recientes en el área de la nanotecnología han abierto nuevos horizontes para la 
BNCT. Los nanomateriales, tras ser administrados por vía intravenosa, tienen la capacidad de 
acumularse de forma pasiva en los tumores gracias al llamado efecto enhanced permeability and 
retention (EPR). Durante el crecimiento tumoral, se produce neo-angiogénesis, de modo que se 
generan nuevos vasos sanguíneos de forma rápida y generalmente desestructurada. Por ese 
motivo, los vasos sanguíneos son imperfectos, dejando huecos por los cuales los nanomateriales 
pueden permear. Este hecho, unido a un drenaje linfático deficitario, facilita la acumulación de 
nanomateriales en los tumores.  
El efecto EPR ha contribuido a que una de las mayores aplicaciones de los nanomateriales en 
biomedicina sea en el desarrollo de fármacos para diferentes tipos de cáncer. En este contexto, el 




gran número de nanosistemas ricos en boro que podrían solventar el problema histórico asociado 
a la BNCT. 
En esta tesis doctoral, se pretende el desarrollo de diversos nanosistemas base oro, con un alto 
contenido en boro, como posibles candidatos para su aplicación en BNCT. Con el fin de probar 
su capacidad de acumularse en el tejido diana (tumor), se han desarrollado diferentes estrategias 
de marcaje con isótopos emisores de positrones (PET), con el fin de permitir su monitorización 
tras administración a animales utilizando tomografía por emisión de positrones.  
En primera instancia (trabajo incluido en el capítulo 3), se optó por la utilización de 
nanopartículas (NPs) de oro (AuNPs) de un tamaño de núcleo alrededor de 20 nm, ya que este es 
un tamaño adecuado para la acumulación de nanomateriales en tumores debido al efecto EPR. 
Con el fin de conferir estabilidad in vivo a las NPs, se decidió incorporar polietilenglicol (PEG) 
en la superficie de las NPs. Asimismo, se incorporó el anión cobalto bis(dicarballuro), 
denominado comúnmente COSAN, un clúster de boro y carbono que contiene 18 átomos de boro 
en la estructura. El anclaje de ambos (PEG y COSAN) en la superficie de las NPs se llevó a cabo 
mediante la bien conocida química de tioles. Las NPs resultantes se caracterizaron mediante un 
conjunto de técnicas, incluyendo microscopía electrónica de transmisión (TEM), dispersión 
dinámica de luz, espectrofotometría UV-Vis, espectroscopía Raman y espectroscopía 
fotoelectrónica de rayos X. Los análisis demostraron la formación de NPs con diámetro de núcleo 
de 19.2±1.4 nm, diámetro hidrodinámico de 37.8±0.5 nm, y un valor de potencial zeta de 
−18.0±0.7 mV a pH neutro. Además, quedó confirmada la presencia de boro en la superficie. Con 
el fin de permitir la realización de estudios in vivo mediante PET, se abordó la incorporación del 
isótopo emisor de positrones yodo-124 tanto en el núcleo (mediante adsorción aniónica sobre la 
superficie de oro) como en la corteza (mediante incorporación del átomo de yodo sobre el clúster 
de boro). Para determinar el tiempo de circulación en sangre y la capacidad de los nanosistemas 
de acumularse en el tumor, se realizaron ensayos en un modelo tumoral de ratón, generado 
mediante inoculación subcutánea de células HT 1080 (fibrosarcoma). Los estudios PET 
demostraron una rápida acumulación de las NPs en el hígado, con la consecuente baja 
biodisponibilidad, que resultó en última instancia en una muy baja acumulación en el tumor. Sin 
embargo, los estudios efectuados con el doble marcaje secuencial demostraron una buena 




Los resultados obtenidos en el capítulo 3 sugirieron la necesidad de modificar las características 
de las NP para prolongar el tiempo de circulación y mejorar la acumulación en tumor. En 
consecuencia, se optó en este segundo trabajo (incluido en el capítulo 4) por preparar y 
caracterizar NPs similares a las incluidas en el capítulo 5, pero con dos tamaños de núcleo 
diferentes, alrededor de los 3 y los 10 nm. En este caso, se optó por una estrategia para el marcaje 
radioactivo basado en la incorporación del isótopo emisor de positrones cobre-64 (64Cu) en el 
núcleo de las NPs, para de este modo minimizar la pérdica del radioisótopo durante los estudios 
in vivo. Las NPs diseñadas demostraron una baja toxicidad in vitro en tres líneas celulares, y una 
buena capacidad de internalización en la línea celular MKN45 (carcinoma gástrico). Tras efectuar 
el marcaje con buena eficiencia, se abordaron estudios de imagen utilizando PET-CT en un 
modelo murino de cáncer, generado mediante inoculación de células MKN45 en ratones 
inmunodeprimidos. Los estudios efectuados con las NPs con tamaño de núcleo de ca. 10 nm 
mostraron una rápida acumulación en el hígado, resultando en una baja biodisponibilidad y en 
consecuencia en una baja acumulación en el tumor a los diferentes tiempos de estudio (1-48h). 
Sin embargo, las NPs con tamaño de núcleo de ca. 3 nm mostraron una mayor circulación en 
sangre, una menor retención en el hígado y una mayor acumulación en el tumor (Figura 2), con 
valores de 5.3±1.3 %de dosis inyectada por cm3 a las 24 horas tras administración. 
Posteriormente, se observe una disminución progresiva en este tejido.  
A pesar de la mejora en la acumulación tumoral obtenida en el capítulo 4, la concentración de 
boro en el tumor puede considerarse insuficiente para abordar los experimentos de eficacia 
terapéutica únicamente atendiendo a la modalidad de BNCT. Por lo tanto, el siguiente paso fue 
diseñar agentes terapéuticos que permitieran la combinación de BNCT con otra modalidad 
terapéutica. Aprovechando la capacidad de los nanorods de oro (GNRs) para interactuar con la 
luz infrarroja para generar calentamiento local, se decidió preparar nanorods de oro 
funcionalizados simultáneamente con PEG y COSAN, de manera similar a lo llevado a cabo en 
los capítulos anteriores. El hecho de disponer de nanorods funcionalizados con moléculas ricas 
en boro debería permitir combinar dos modalidades terapéuticas, BNCT y terapia fototérmica. La 
síntesis y funcionalización de los NRs se llevó a cabo mediante métodos previamente 
establecidos, si bien se ajustaron los parámetros experimentales para obtener nanosistemas con un 
tamaño de núcleo de 37±3 × 10±1 nm (ratio de aspecto de 3.7), según demostraron los estudios 




mediante análisis por EDX y espectrofotometría UV-Vis. Los GNR resultantes mostraron buena 
capacidad de internalización en células MKN45 y baja toxicidad tanto en células MKN45 como 
en fibroblastos dérmicos humanos (células HDFa).  
 
Figura 2. Imágenes PET (vistas coronales y axiales) representativas, obtenidas a las 1, 6, 24 y 48 horas 
después de la administración de NPs con tamaño de núcleo de ca. 3 nm, marcadas con 64Cu, en un modelo 
animal de ratón generado por inoculación subcutánea de células MKN-45. Las imágenes PET son 
proyecciones de máxima intensidad, y se muestran corregistradas con cortes representativos de imágenes 
CT correspondientes al mismo animal, para facilitar la localización de la señal radiactiva. La posición del 
tumor se indica con flechas blancas. 
Posteriormente, se abordó el marcaje de los GNRs con un isótopo emisor de positrones, en este 
caso 64Cu, que se incorporó en el núcleo mediante proceso de reducción in situ en presencia de 
hidracina. El marcaje mostró alta estabilidad en diferentes medios de incubación. Finalmente, se 
aboradron estudios de biodistribución in vivo en un modelo tumoral de ratón generado por 
inoculación de células MKN45. Los GNRs mostraron una buena acumulación en el tumor, con 
valores por encima del 3% de dosis inyectada por gramo de tejido, y ratios de concentración 
respecto a tejido sano favorables a las 24-48 horas tras la administración (Figura 3). 
La acumulación en tumor de los GNRs permite anticipar que sería posible llevar a cabo estudios 
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Figura 3. mágenes PET (vistas coronales) representativas, obtenidas a las 1 (a), 4 (b), 24 (c) y 48 (d) 
horas después de la administración de GNRs marcados con 64Cu, en un modelo animal de ratón generado 
por inoculación subcutánea de células MKN-45. Las imágenes PET son proyecciones de máxima 
intensidad, y se muestran corregistradas con cortes representativos de imágenes CT correspondientes al 






Chapter 1 – General introduction 
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Chapter 1: General Introduction 
1.1 The global burden of cancer 
Cancer is a disease that occurs when cellular changes cause the uncontrolled growth and division 
of cells. According to the World Health Organization (WHO), cancer is still one of the leading 
causes of death worldwide, accounting for about 1 in every 6 deaths. In 2018, there were 18.1 
million new cases of cancer diagnosed around the world and caused 9.6 million deaths [1]. By 
2040, the global cancer incidence is expected to reach 27.5 million new cancer cases and 16.3 
million cancer deaths, due to the aging of the population. Unfortunately, cancer is a 
heterogeneous disease, which makes treatment difficult. Currently, chemotherapy, radiotherapy, 
immunotherapy, and surgery are the main treatment options established in the clinical field. 
However, the efficacy of all these approaches is compromised by their risk to normal, healthy 
cells, and their potential to destroy the immune system. Therefore, a large body of cancer therapy 
research focuses on developing effective alternative treatments that can replace conventional 
therapies by improving therapeutic efficacy and reducing off-target side effects. 
1.2 Boron Neutron Capture Therapy 
1.2.1 General description 
Boron neutron capture therapy (BNCT) is a promising radiotherapeutic modality to treat cancer. 
Gordon Locher was the first person to propose the concept of BNCT in 1936 [2]. This binary 
therapeutic modality is based on the neutron capture and nuclear fission reactions that occur 
when the non-radioactive stable atom boron-10 (~ 20% of natural boron) is irradiated with low 
energy thermal neutrons (E < 0.5 eV) or high energy epithermal neutrons (0.5 eV < E < 10 eV) to 
yield high energy alpha particles (α2+ = 4He2+) and recoil lithium ions (7Li3+) (Figure 1.1).  Alpha 
particles and 7Li recoil ions have high linear energy transfer (LET) properties (150 keV µm-1 and 
175 keV µm-1, respectively) and path lengths in the range of 4 to 10 µm. Thanks to their strong 
ionization capacity, these particles are capable to create localized damage within the diameter of 
a single cell. Hence, if cancer cells selectively accumulate a sufficient amount of 10B and are 
irradiated with thermal or epithermal neutrons, the ions produced as a consequence of the 10B(n, 
α, γ)7Li nuclear reaction trigger cell death, while sparing healthy surrounding tissue and 
decreasing unwanted off-target side effects (Figure 1.2). 




Figure 1.1. 10B(n, α, γ)7Li nuclear reaction. The neutron is captured by the boron-10 atom, resulting in the 
formation of an unstable 11B atom which rapidly undergoes a fission reaction with subsequent emission of 
one alpha particle, one recoil lithium ion and one gamma ray.  
 
Figure 1.2. The principle behind BNCT: 10B atoms preferentially accumulate in cancer cells (1). Neutron 
beam irradiation (2) produces the rapid nuclear reaction 10B(n, α, γ)7Li. Alpha particles and 7Li ions have 
high linear energy transfer, triggering cell damage while sparing healthy surrounding tissue. 
1.2.2 Boron delivery agents: Ideal properties 
To find application in BNCT, drugs must fulfill certain requirements: (i) they should be able to 
selectively accumulate 20-35 µg of 10B (natural abundance of 10B 19.9%) per gram of tumor, 
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preferentially inside the cells, in order to guarantee that a sufficient amount of neutrons is 
absorbed producing the above mentioned nuclear reaction; (ii) they should show rapid clearance 
from blood and healthy tissues, in order to prevent damage in surrounding tissue during neutron 
irradiation; it is generally accepted that tumor-to-normal tissue (TtT) and tumor-to-blood (TtB) 
concentration ratios above 4-to-1 are sufficient to minimize off-target damage; (iii) they must 
exhibit low systemic toxicity since they are usually injected intravenously; and (iv) ideally, they 
should incorporate a means for external tracking in real time, in order to identify the optimal time 
window for neutron irradiation after administration of the drug. To date, many different drug 
candidates over a wide range of molecular modalities have been developed. A brief overview of 
the most relevant examples is provided below from an historical perspective.  
1.2.3 First and second-generation boron delivery agents.  
First compounds proposed as BNCT drug candidates were small molecules containing boron 
atoms in their structure. In the 1950s and early 1960s, BNCT clinical trials were conducted using 
boric acid and some of its derivatives. These chemical compounds were nonselective and had 
poor tumor retention. Hence, low TtT ratios could be achieved [3, 4]. In the 1960s, second-
generation compounds covering a wide variety of small molecules emerged, being the two most 
prominent examples sodium mercaptoundecahydro-closo-dodecaborate (Na2B12H11SH), 
commonly known as sodium borocaptate or BSH [5], and the boron-containing amino acid (L)-4-
dihydroxy-borylphenylalanine [6], known as boronophenylalanine or BPA (Figure 1.3). 
BSH, a polyhedral mercaptoboron molecule, was first applied to patients in 1968 [7] for the 
treatment of tumors in the central nervous system (CNS). Subsequent clinical trials using this 
boron-rich compound were focused in the treatment of patients with brain tumors [8-10], while 
BPA was also evaluated in patients suffering from malignant melanoma [11]. Despite the positive 
results, the major drawback of both BSH and BPA is the low selectivity and the significant inter-
subject variability in tumor uptake, especially in brain tumors, as demonstrated by Goodman and 
co-workers. In a biodistribution and pharmacokinetic study involving 20 patients with high-grade 
gliomas [8], the authors found that boron concentrations varied among patients who received the 
same dose of BSH. Additionally, heterogeneous tumor accumulation was also observed. In spite 
of these drawbacks, BSH and BPA are still the only compounds used in the clinical field [12], 
suggesting the need for further investigation.  




Figure 1.3. Chemical structures of boric acid (left), sodium borocaptate (BSH, middle) and 
boronophenylalanine (BPA, right). 
1.2.4 Third-generation boron delivery agents.  
Polyhedral heteroboranes, and more specifically dicarba-closo-dodecaboranes (commonly 
referred to as carboranes) with the general formula C2B10H12, have been extensively used as 
boron-rich structures for the preparation of third-generation boron delivery agents. Carboranes 
exist as ortho-, meta-, and para-isomers (Figure 1.4), which differ in the relative positions of the 
carbon atoms in the cluster. The cobalt bis(dicarbollide) anion [3,3’-Co(1,2-C2B9H11)2]- (Figure 
1.4) is a stable complex in which the cobalt atom is held between two η5-bonding [C2B9H11]2- 
ligands derived from nido-carborane, which can be obtained by withdrawing one of the boron 
atoms adjacent to both Cc atoms in the o-carborane cluster [13].  
 
Figure 1.4. Chemical structure of ortho-, meta- and para-carborane and the cobalt bis(dicarbollide) anion. 
White dots denote B-H; black dots denote C-H; blue dot denotes Co(III). 
Third-generation compounds mainly consist of a stable boron group or cluster connected via a 
hydrolytically stable linkage with a low molecular weight biomolecule, which is expected to aid 
Chapter 1 – General introduction 
5 
 
in tumor accumulation by acting as a vector. Commonly used vectors include amino acids [14, 
15], peptides [16, 17], nucleosides [18], carbohydrates [19] and porphyrins [20, 21].  
The use of boron-rich antibodies (Abs) has also been proposed, due to their exquisite selectivity 
towards the epitope. It is estimated that a boronated Ab should contain 103 10B atoms per Ab unit 
to provide a therapeutic dose to the tumor [22], but the incorporation of such a large amount of 
boron results in a significant loss of immunoreactivity and hence therapeutic efficacy might be 
compromised.  
In spite of more than 50 years of efforts and considerable advances, a third generation compound 
suitable for application in the clinical practice has not been found. At his point, the emergence of 
nanotechnology opened new opportunities in the pursuit of effective and safe boron delivery 
agents. 
1.2.5. Nanostructures for BNCT 
Nanomedicine involves the use of nanoscale materials, e.g. nanoparticles (NPs), for the 
diagnosis, monitoring and/or treatment of diseases. Nanoparticles are generally defined as small 
particles with dimensions approximately from 1 to 100 nm according to the American Society for 
Testing and Materials (ASTM international 2006). NPs have unique physical and chemical 
properties compared to their bulk materials, including a large surface area-to-volume ratio, and 
exclusive optical and electrical properties [23]. Due to their small size, and depending on their 
composition and surface-functionalization, NPs can show high biocompatibility and can carry a 
significant amount of cargo. Hence, they have been proposed as drug delivery agents, especially 
in cancer applications because of their capacity to passively accumulate in tumor tissue. Indeed, 
tumor growth is accompanied by angiogenesis. In this process, rapid blood vessel formation leads 
to imperfect vessel walls with large fenestrations, which facilitate extravasation of large 
circulating entities (e.g. NPs) from the blood vessel to the tissue. This, together with a 
compromised lymphatic drainage, favors tumor accumulation of nanomaterials after intravenous 
administration. This process is known as enhanced permeability and retention or EPR [24] 
(Figure 1.5).  




Figure 1.5. Schematic illustration showing nanoparticles accumulation in tumor due to enhanced 
permeability and retention (EPR) effect. 
The passive targeting via enhanced permeability and retention effect has been widely exploited to 
accumulate different drugs in tumors, also in the context of BNCT. The clearest example on the 
use of nanosized materials to achieve high accumulation of boron in tumors are liposomes, which 
proven capable to accumulate large amounts of drugs in cancer cells [25-27]. Moreover, 
liposomes can be conveniently functionalized with antibodies, peptides, or other targeting 
moieties which may enhance retention in the tumor or cell internalization via specific interaction 
with receptors over-expressed in cancer cells [28, 29]. Similar to other drugs, BNCT agents can 
also be encapsulated inside liposomes, which passively accumulate in the tumor where the cargo 
is released via diffusion through the liposome or by degradation. This has been demonstrated in 
several works, showing promise for their translation to the clinical setting [30]. For example, 
Hawthorne and coworkers have designed a liposome system containing boron not only in the 
aqueous core but also in the lipid bilayer, which showed BNCT efficacy in a mouse model of 
mammary adenocarcinoma [31] (Figure 1.6a).  
Other nanosystems have been employed to accumulate boron atoms in tumors, taking advantage 
of the EPR effect. One example is dendrimers, which thanks to their structure can be 
functionalized with a large number of boron cages. These can be attached to antibodies, in order 
to achieve high boron content without severely compromising the immunoreactivity of the 
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polyamidoamine dendrimer BD‐C225 was linked with cetuximab (Figure 1.6b). This compound 
showed BNCT efficacy in EGFR gene‐transfected rat glioma cells [32] 
a b
 
Figure 1.6. Schematic representation of boronated liposomes (a) and boronated polyamidoamine 
dendrimer (BD-C225) (b). Reprinted with permission from original sources [31] and [33].  
Carbon nanotubes (CNTs) have also attracted great attention in biomedical applications due to 
their unique properties such as high thermal stability, magnetic properties, excellent conductivity, 
and superb chemical and mechanical properties [34]. CNTs are widely used in therapeutic drug 
delivery due to their high surface area and nanodimensionality, which allows them to adsorb or 
conjugate with a wide variety of therapeutic drugs. Additionally, surface engineered (i.e., 
functionalized) CNTs enhance their solubility and biocompatibility, resulting in low cytotoxic 
effects in therapeutic drug delivery [35]. In the context of BNCT, CNTs have been modified with 
nido-carborane units [36]. These water-soluble CNTs were tested in 3T3 fibroblasts and HL60 
cells, where it was found that CNTs were able to transport large amount of functional groups into 
cells without apparent toxicity (Figure 1.7a).  
Besides CNTs, boron nitride nanotubes (BNNTs) have also been proposed as BNCT drug 
candidates due to their inherent boron content. For example, transferrin coated boron nitride 
nanotubes (tf-BNNTs) were tested on human umbilical vein endothelial cells (HUVEC), as 
model of the BBB endothelium. Results revealed that transferrin played a key role during 
internalization of tf-BNNTs by HUVEC [37] (Figure 1.7b).   






Figure 1.7. Carbon nanotubes (CNTs) decorated with nido-carboranes (a) and transferrin conjugated 
BNNTs (b). Reprinted with permission from original sources [36] and [37] 
Boron phosphate (BPO4) has also been used for the preparation of nanosized BNCT agents. In 
one example of targeted approach, folic acid conjugated BPO4 NPs were prepared with amine 
terminated BPO4 and folic acid via condensation reaction [38]. However, these functionalized 
BPO4 NPs showed high cytotoxicity in several cell lines.  
Besides the above mentioned examples, other boron rich nanosystems have been prepared and 
eventually evaluated in the context of BNCT. These include magnetic nanoparticles [39], 
borosilicate nanoparticles [40], and polymeric NPs [41, 42]. 
1.2.6. Gold nanoparticles: potential boron carriers for BNCT  
Gold nanoparticles (AuNPs) are extensively investigated NPs and have potential applications in 
medicine due to their unique physical and chemical properties, which significantly differ from the 
bulk material. The attractive features of AuNPs include their low level of toxicity, easy 
modification, biocompatibility, tunable stability and optical properties, and small dimensions. 
Additionally, they have straightforward functionalization chemistry through the well-known 
sulfur-gold bond formation. These unique features turn AuNPs into excellent candidates for a 
wide range of biomedical applications including drug delivery, cancer treatment, biomedical 
imaging, diagnosis and many others. 
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There are several ways of synthesizing AuNPs. They can be divided into physical, chemical and 
biological methods, although the most common approach is via chemical methods, which offer 
the possibility to precisely controlling the size and shape of the NPs. Indeed, AuNPs with 
different shapes can be synthesized including nanospheres, nanoshells, nanorods, nanoclusters, 
nanocages, and nanostars, among others [43-45] (Figure 1.8).  
 
Figure 1.8. Different forms of gold nanoparticles (reprinted with permission from original source [45]) 
Among different forms of AuNPs, gold nanospheres are the simplest nanostructures of gold and 
can be synthesized by controlled reduction of an aqueous solution of HAuCl4 using a reducing 
agent such as citrate ion (sodium salt of citric acid) [46]. Citrate ion acts both as a reducing agent 
and also as particle stabilizer. The size of gold nanospheres can be easily tuned by varying the 
amount of reducing agent and gold precursor. This method has greatly impacted the preparation 
of biomedical-grade AuNPs in the range of 20 nm. Brust et al. developed a one pot protocol to 
synthesize gold nanospheres in the range of 1.5 nm to ∼6 nm. In this preparation, the aqueous 
HAuCl4 solution is transferred to an organic phase (e.g. toluene) using tetraoctylammonium 
bromide (phase-transfer agent) and reduced with NaBH4 in the presence of a thiol ligand 
(stabilizer) [47]. In this process, the thiol ligand/gold stoichiometry affects the size of the 
nanospheres. To get smaller and monodisperse gold nanospheres, faster addition of the reducing 
agent in a cooled solution to the thiol/gold precursors is mandatory. Later, this method was 
modified in different ways to achieve shape and size control, as well as to incorporate 
functionalities on the surface. 
Gold nanospheres exhibit a strong absorption band in the visible region due to the collective 
oscillations of electrons in the conduction band in strong resonance with frequencies of visible 
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light. This phenomenon is called surface plasmon resonance (SPR) (Figure 1.9a, A). This effect 
induces a strong absorption of the light that depends on different properties including size, shape, 
surface functionality and aggregation state of the particles; when the size of the gold nanosphere 
is increased, the plasmon shifts towards higher wavelengths (Figure 1.9b, B). 
Gold nanorods (GNRs), which are rod-shaped nanomaterials, have gained special attention in 
biological/biomedical fields, especially in the context of photothermal therapy, biosensing, 
imaging, and gene delivery for the treatment of cancer. Because of their rod-like shape, SPR 
spectrum exhibits two absorption bands: the first band stems from the visible region (around 520 
nm) due to the interaction of light with the electrons from the diameter width, and the second one, 
red-shifted, stems from the NIR region (around 780 nm) due to the interaction of light with 
electrons from the length width of the nanorods (Figure 1.9b, B). The aspect ratio of GNRs 
affects the absorption spectra, with higher aspect ratios resulting in a shift towards higher 
wavelength values. 
 
Figure 1.9. (a, A) Schematic representation of LSPR excitation for gold nanospheres; (a, B) typical LSPR 
absorption band of gold nanospheres; (b, A) Schematic illustration of LSPR excitation for GNRs and (b, 
B) LSPR absorption bands of GNRs: longitudinal and transverse plasmon bands corresponding to the 
electron oscillation along the long axis (b, A (top)) and the short axis (b, A (below)) of GNR, respectively 
(reprinted with permission from original source[48]) 
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Several methods have been reported to synthesize GNRs, including both seed-mediated and 
seedless mediated methods [49, 50]. The seed-mediated growth method is the most widely used 
approach to synthesize GNRs with different aspect ratios by changing the stoichiometry of gold 
seeds and gold tetrachloride in the presence of the surfactant. In this method, a known amount of 
gold seeds are added to the growth solution which contains cetyltrimethylammonium bromide 
(CTAB) as the surfactant. The seeded crystals grow into GNRs with a certain aspect ratio with 
the help of surfactant. Recently, Ye et al. reported a new method for the synthesis of GNRs by 
seed-mediated growth method [51]. In this method, aromatic salicylates are used as an additive to 
improve the CTAB-micelle interaction, leading to a more stable structure, and resulting in the 
formation of monodispersed GNRs with high yield.  
The use of gold-based nanomaterials in the context of BNCT is not widely exploited, although 
some examples can be encountered in the literature. In one of the first examples reported in 
which gold NPs were proposed as potential BNCT agents, Cioran et al. described the use of 
mercaptocarborane as a capping agent on the AuNPs via Au-thiol interaction (Figure 1.10a) [52]. 
These NPs displayed high cellular uptake due to the oxidation of NPs. However, these NPs 
showed high toxicity towards HeLa cells. In another study, ortho-carborane moieties were 
incorporated onto PEG-stabilized AuNPs through click chemistry. The addition of PEG resulted 
in water soluble functionalized AuNPs. The stability of these NPs and their capacity to 
accumulate in tumors, however, remains to be investigated (Figure 1.10b) [53].  
 
Figure 1.10. Mercaptoborane-capped AuNPs (a) and PEG-stabilized AuNPs incorporating ortho-
carboranes (b) (reprinted with permission from original source [33]) 
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1.3. Tracking NPs in vivo: Nuclear Imaging 
As mentioned in the previous sections, nanoparticles (NPs) have been widely applied as drug 
delivery agents, especially in cancer applications where they can preferentially accumulate in the 
tumor thanks to the EPR effect. However, in most scenarios NPs are extremely difficult to detect 
and quantify once distributed in a biological system. Hence, the determination of the 
pharmacokinetic properties and biological fate of NPs becomes an extremely challenging task. 
Such determination is especially relevant in the context of BNCT, because neutron irradiation 
needs to be applied when the concentration of boron in the tumor is maximum, and the 
concentration of boron both in blood and in surrounding tissue are low, the latter to prevent off-
target side effects. Hence, a suitable tool for the determination, in vivo and in real time, of the 
concentration of boron in at the whole body level is paramount in order to predict therapeutic 
efficacy and select the optimal time-window for neutron irradiation.  
When using small experimental animals (e.g. rodents such as mice and rats), this information can 
be obtained after animal sacrifice by classical chemical analysis of the different organs to identify 
elements or molecules from the nanoparticles. The results can then be extrapolated to other 
animals to evaluate treatment efficacy. However, this requires animal sacrifice, and hence results 
have to be extrapolated from one group of individuals to other groups, as the biodistribution is 
not evaluated in a case-by-case basis. Additionally, natural or background levels of chemical 
components may be mistakenly considered as the signature of NPs presence. Finally, this 
approach cannot be translated to the clinical setting and is ethically questionable in large animal 
species.  
One alternative to overcome this problem consists of labeling the NPs with radionuclides that can 
lead to their detection in biological systems by means of nuclear imaging techniques, this is, 
Positron Emission Tomography (PET) or Single Photon Emission Computerized Tomography 
(SPECT), which are in vivo, minimally invasive and very sensitive molecular imaging 
techniques. The most critical part in this approach is the incorporation of the radionuclide into the 
NP, and to date different strategies have been developed. The selection of the strategy for the 
radiolabeling depends on many different factors, e.g. the radionuclides available, the chemical 
composition of the NPs or the physical half-lives of the radionuclides. In the current PhD thesis, 
PET imaging has been used to assess the biodistribution of newly developed NPs and to 
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investigate tumor accumulation. Because of this, a brief introduction covering the principles of 
nuclear imaging and PET in particular are included below. A brief description of the 
radionuclides used in the context of the PhD thesis and the most common labeling strategies 
applied with those radionuclides is also included.   
1.3.1. Positron emission tomography  
Nuclear imaging techniques rely on the administration of small amounts of radioactive materials 
called radiotracers or radiopharmaceuticals, i.e., a compound labeled with a positron or gamma-
emitting radionuclide. When a positron or gamma-emitter disintegrates, high energy gamma rays 
are ultimately generated. Gamma rays can travel through biological tissues without suffering 
significant scatter or attenuation. These gamma rays (or high energy photons) can be detected by 
specific equipment in such way that the original concentration of the radiotracer can be 
accurately quantified using specific tomographic reconstruction algorithms. Positron emission 
tomography (PET), single photon emission computed tomography (SPECT) and planar 
scintigraphy are nuclear imaging techniques. Nowadays, these techniques are available in 
combination with anatomical imaging such as computerized tomography (CT) or magnetic 
resonance imaging (MRI). 
Positron emission tomography (PET) is the most sensitive nuclear imaging technique. This 
technique relies on the detection of the coincident high energy gamma rays (or high energy 
photons) resulting from the emission of a positron emitting radiotracer. Typical positron emitters 
used in the biomedical field include Fluorine-18, Carbon-11, Nitrogen-13, Oxygen-15, Galium-
68, Copper-64, Zirconium-89 and Iodine-124. 
In positron emission tomography, a PET radiotracer (any molecule labeled with a positron 
emitter) is administered to the subject under investigation. The spontaneous radioactive decay of 
a positron emitter produces a positron, which travels a certain distance (positron range; typically 
a few millimeters in water) to finally annihilate with the electron of a surrounding atom. As a 
result of the annihilation process, two gamma photons (511 keV each) are emitted in opposite 
direction (Figure 1.11). These high energy gamma rays can travel though biological tissues 
without suffering significant attenuation or scattering effects. Hence, they can be detected by an 
external ring of detectors (placed around the investigated subject) as coincident events. When two 
detectors detect two gamma rays simultaneously, a line of response is generated, so as the 
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disintegration took place somewhere within this line. The detection of hundreds of thousands of 
coincident events permits the accurate reconstruction of three-dimensional images that contain 
information about the spatiotemporal distribution of the radiotracer within the organism.  
e-
 
Figure 1.11. Schematic representation of the detection of photons using PET. (A) The positron travels a 
certain distance (positron range) and annihilates with an electron, resulting in the emission of two gamma 
rays in opposite direction; (B) the two gamma rays resulting from the annihilation are detected as a 
coincidence event by two detectors. Hence, a line of response is defined. 
In order to get high quality PET images, the selection of the right positron emitter is paramount. 
In table 1.1, half-life values (time required to decrease the number of radioactive atoms to one 
half) and the energies of the emitted positrons for the most widely used PET radionuclides in the 
biomedical field are shown. Both half-life and energy of the emitted positron are indeed key 
factors to be considered.  
The energy of the positron defines the positron range. The longer the positron range is, the higher 
the distance between the location of the disintegration event and the location of the annihilation. 
Hence, larger positron energy values usually result in lower resolution images. The other key 
parameter is physical half-life of the radionuclide, as this should match the biological half-life of 
the molecule to be investigated, in our case the NPs. If the physical half-life of the radionuclide is 
too short, NP tracking will be only possible during a short period of time after injection (4-5 half-
lives), and hence the biological process will be only partially investigated. If the half-life is too 
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long, the investigated subject will be submitted to a higher radiation dose and waste disposal will 
be more costly.  
Table 1.1. Physical properties (half-life and positron energy) of the most commonly used positron 






18F 109.8 min 0.63 MeV (0.97) 
11C 20.4 min 0.96 MeV (1.00) 
13N 9.97 min 1.20 MeV (1.00) 
15O 122 sec 1.73 MeV (1.00) 
68Ga 67.7 min 1.89 MeV (0.89) 
64Cu 12.7 hours 0.66 MeV (0.18) 
89Zr 78.4 h 0.90 MeV (0.23) 
124I 4.18 days 2.14 MeV (0.23) 
 
1.3.2. Positron emitters for NP labeling 
When dealing with NPs, as they show long residence time in the body, long-lived radionuclides 
are perceived to be appropriate. Among the most commonly used positron emitters (see Table 
1.1), mainly Copper-64 (64Cu), Iodine-124 (124I) and Zirconium-89 (89Zr) have appropriate 
physical half-lives for the purpose. In this PhD thesis, Copper-64 and Iodine-124 have been used 
for radiolabeling the nanosystems. Therefore, the preparation methods, main properties and 
radiolabeling strategies concerning these radionuclides are briefly presented below. 
Copper-64 
Copper-64 (64Cu) has a physical half-life of 12.7 h, which enables in vivo tracking of the labeled 
entity over a period of a few days. 64Cu is effectively produced by both reactor- and accelerator-
based methods. Reactor based methods usually entail the irradiation of materials with thermal or 
fast neutrons. Thermal neutrons have relatively low energy; in low energy neutron irradiation 
processes, the target (irradiated) material is of the same element as the product radionuclide; 
therefore, low-specific activity radionuclides are obtained. 64Cu, for example, can be produced by 
irradiation of stable 63Cu (69.1% natural abundance) with thermal neutrons via the 63Cu(n,γ)64Cu 
nuclear reaction. However, if this approach is used, 64Cu will be “diluted” with the starting 63Cu. 
Both isotopes cannot be separated, and hence low specific activity of the radionuclide is obtained. 
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This implies certain limitations, although discussion is beyond the scope of this thesis. For the 
production of high-specific activity 64Cu, fast neutrons can be used. Unlike a thermal neutron, a 
highly energetic neutron has sufficient energy to eject a particle from the target nucleus, and the 
irradiated material can undergo (n,p) reactions. Thus, 64Cu can be efficiently produced from 64Zn 
via the 64Zn(n,p)64Cu nuclear reaction [54]. The main drawback of this methodology arises from 
the fact that fast neutron reactions using reactor neutrons are always accompanied by thermal 
neutron reactions, which may produce significant quantities of undesirable impurities. 
Alternatively, 64Cu can be effectively produced using biomedical cyclotrons via the 64Ni(p,n)64Cu 
nuclear reaction [55]. For the production, enriched 64Ni is electroplated on to a gold disk and is 
irradiated with 14-16 MeV protons. After irradiation, the target material is dissolved in 
concentrated HCl and the solution is passed through an ion exchange column with different acid 
concentrations to separate 64Cu from the target nickel and other impurities. The enriched 64Ni can 
be successfully recovered and used for subsequent production and labeling experiments. 
Despite the half-life of copper-64 is appropriate to investigate chemical species with long 
residence time in the organism, its decay scheme is far from optimal for PET studies. 64Cu decays 
by ꞵ- emission to the ground state of 64Zn (ꞵ- = 38.48 %) and by ꞵ+ emission to 64Ni (ꞵ+ = 17.52 
%) with 43.8 % electron capture (EC) (Figure 1.12) [56]. The positron-branch makes it a useful 
candidate for diagnostic imaging, while the beta-minus branch along with the emission of Auger 
electrons following electron-capture decay make it an attractive candidate also for therapy. 
However, the low positron branching is a limitation when used exclusively for imaging purposes, 
as almost 85% of the radioactive decay is not detected by the PET camera. 
 
Figure 1.12. 64Cu decay scheme (adapted from [57]) 




Copper is a thoroughly explored element with well-known coordination chemistry. Because of 
this, the most traditional approach to attach 64Cu to NPs is via a metal chelator. In this traditional 
radiolabeling approach, 64Cu is conjugated to the surface of NPs through macrocyclic chelators 
such as 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA), previously attached 
via covalent bonds to the surface of the NP. Although this approach has the advantage that the 
radiolabeling is carried out at the very late stage of the process, thus minimizing radiation 
exposure and loss of radioactivity due to radioactive decay, it also has a few disadvantages, 
including the possible detachment of radiometal from the complex, that may lead to 
misinterpretation of the images [58], and the modification of the surface properties of the 
nanoparticle. As an lternative with particular application to gold NPs, Zhao et al. recently 
reported a chelator‐free 64Cu radiolabeling strategy for gold nanoparticles via formation of an Au-
64Cu alloy [59]. They were able to radiolabel the AuNPs and investigate the capability of the 
resulting nanosystems to accumulate in the tumor in a mouse breast cancer model using a 
PET/CT. This labeling protocol results in the formation of highly stable labeled NPs, paving the 
way towards reliable in vivo evaluation of gold NPs using PET imaging.  
Iodine-124  
Iodine 124 (124I) is a positron emitter with a long half-life (4.17 days) playing an important role in 
nuclear medicine for long-term clinical and PET studies. 124I can be produced using different 
nuclear reactions. Generally, 124I is produced in solid targets. The most widely used strategy is 
the irradiation of enriched 124Te via the 124Te(p,n)124I or the 124Te(d,2n)124I  nuclear reactions 
[60]. The irradiated material is tellurium or tellurium oxide, and 124I is recovered easily from the 
irradiated material by dry distillation, or by dissolution of the target in oxidizing alkaline medium 
followed by reduction of tellurium and iodine and purification using solid phase extraction. 
Iodine-124 has complex radioactive decay scheme (Figure 1.13) [61], which includes several 
high-energy gamma emissions (0.603 MeV, 63.0% abundance) and high energy positron emission 
(Eþmax = 2.14 MeV, 23% abundance). As in the case of 64Cu, the emission spectrum is not optimal 
for application in PET imaging. However, due to its long half-life, it finds application when the 
user of more convenient radionuclides (from an emission spectrum point of view) cannot be 
applied.   









Figure 1.13. Simplified decay scheme of 124I (adapted from [61])  
In general terms, radiolabeling with 124I can be approached using three main synthetic routes: (i) 
direct incorporation into activated aromatic rings by electrophilic substitution using the anionic 
species of the radionuclide (I-) in the presence of oxidizing reagents, e.g. chloramine-T or N-
chloro tosylamide [62]. In this chemical reaction, iodide in oxidation state −1 is oxidized to form 
a reactive electrophilic species in the oxidation state +1, which simply substitutes an hydrogen 
atom on aromatic rings containing electron-donating groups. The method is simple and usually 
high yields are obtained, although the reaction conditions may compromise the stability of the 
chemical entity to be labeled. Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril) is another 
alternative oxidizing agent [63], which was developed to conduct the reaction under milder 
conditions to prevent the damage of labeled molecules by oxidation. This strategy is widely 
applied to the molecules like proteins and antibodies containing tyrosine (or histidine) residues; 
(ii) the covalent attachment of pre-labeled prosthetic groups to the biomolecule. The most 
common conjugation reagent is N-succinimidyl 3-(4-hydroxyphenyl) propionate (Bolton–Hunter 
reagent) [64], which readily reacts with primary amines to form the corresponding amides; and 
(iii) nucleophilic substitution reaction using radioiodine to replace a stable iodine atom (isotopic 
exchange reaction) in the molecule under investigation [65]. In this isotopic exchange reaction, 
both starting material and radiolabeled molecule have the same chemical structure, and hence low 
molar activity values are achieved. 
The three methodologies briefly described above have been extremely useful for the 
radiolabeling of chemical entities over a wide range of molecular modalities, ranging from small 
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molecules to large proteins and antibodies. In the context of NPs, another strategy has been 
developed, which has been very useful in the context of this PhD thesis. This methodology is 
based on the well-known affinity of iodide towards gold. The relative binding strengths of gold 
halide ions are in the order of I > Br > Cl. Iodine has a high affinity for AuNPs via chemisorption 
to the particle surface, and hence iodine labeling on gold surface can be achieved quickly and 
efficiently by simply incubating the nanoparticles with the radioactive anion. This strategy has 
been exploited using different radioisotopes of iodine, including 125I [66], and 131I [67]. However, 
to the best of our knowledge, this strategy has not been applied so far to radiolabeling of NPs 
using the positron emitter 124I.  
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Chapter 2: Motivation and objectives 
2.1. Motivation 
This PhD thesis has been conducted in the Radiochemistry and Nuclear Imaging Group at CIC 
biomaGUNE, led by Dr. Llop. One of the main research lines of the group during the last years 
has been focused in merging the experience gained in boron chemistry and radiochemistry, with 
the ultimate goal of developing potential therapeutic agents with application in boron neutron 
capture therapy (BNCT), and evaluate their suitability in relevant animal models using in vivo 
imaging techniques, mainly positron emission tomography (PET) in combination with anatomical 
techniques, i.e. computerized tomography (CT).  
Previous works performed by other PhD students in the group have focused on the development 
of small molecules containing boron clusters and labeled with positron emitters [1-5]. Despite 
some of these compounds could be successfully labeled, preliminary evaluation in vivo showed in 
most of the cases unfavorable pharmacokinetic properties.  
Recently, and taking advantage of the knowledge gathered at CIC biomaGUNE in the area of 
nanotechnology, the Radiochemistry and Nuclear Imaging Group has progressively incorporated 
nanoparticles in the development of drug candidates for BNCT, often in collaboration with other 
groups within the institute. This PhD thesis is the first example in the group of gold nanoparticles 
(AuNPs) used as boron carriers.  
The first approach (described in chapter 3) was the development of spherical AuNPs with a core 
diameter close to 20 nm (as we expected this to be an ideal particle size for tumor accumulation) 
functionalized simultaneously with Poly(ethylene glycol) methyl ether thiol and the inorganic, 
boron-based molecule cobalt bis(dicarbollide), [3,3’-Co(1,2-C2B9H11)2]-, commonly known as 
COSAN. The resulting multifunctionalized NPs were radiolabeled with 124I to enable in vivo 
tracking. Additionally, and in order to investigate also the biological fate and stability of the NPs 
in vivo, the radiolabel was incorporated both at the core and at the shell of the NPs. Whole body 
imaging studies using PET demonstrated good stability of the NPs, although low accumulation 
was observed in the tumor when evaluated in a mouse xenograft model, generated by 
subcutaneous inoculation of HT 1080 (human fibrosarcoma) cells. Additionally, accumulation of 
radioactivity was observed in stomach and thyroid gland at long times after administration, 
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suggesting progressive release of the radiolabel. This work, which was recently published [6], 
suggests that: (i) particle size was not appropriate for tumor accumulation, as major accumulation 
was observed in the liver; and (ii) the labeling strategy should be improved.  
In view of these previous results, we tackled the investigation of spherical particles with two 
different sizes, around 3 and 10 nm core size, respectively. Additionally, we modified the 
labeling strategy, by incorporating the radionuclide (in this case, 64Cu) at the core of the NPs. We 
also decided to change the tumor model, and assayed a xenograft mouse model generated by 
subcutaneous administration of MKN45 (human gastrointestinal adenocarcenoma) cells. In this 
case, whole body imaging studies using PET demonstrated the increased capacity of the newly 
developed particles to accumulate in the tumor, with higher accumulation for the smaller NPs. 
Additionally, combination of PET studies with ex vivo inductively coupled plasma-mass 
spectrometry (ICP-MS) studies demonstrated good correlation, proving thus the stability of the 
label and the reliability of PET results. The manuscript corresponding to this work is currently 
under preparation.  
In spite of the improved results, tumor accumulation was not sufficient to guarantee therapeutic 
efficacy. In view of this, we decided to investigate boron-rich gold-based nanosystems enabling 
dual therapeutic approaches, i.e. BNCT combined with photothermal therapy (chapter 5). With 
that aim, we developed and evaluated in the same tumor model gold nanorods (GNRs) again 
functionalized simultaneously with PEG and COSAN. The resulting multifunctionalized GNRs 
were radiolabeled with 64Cu following a parallel strategy to that used in chapter 4. In vivo PET 
studies confirmed good tumor accumulation. Although not proven, the presence of boron-rich 
GNRs in the tumor should enable combined therapy. This work, which should prove efficient 
therapeutic effect, is currently ongoing in the research group, although the results have not been 
included in this PhD thesis.  
2.2. Objectives 
The main goal of the PhD thesis was to develop gold-based, boron-rich nanosystems as 
therapeutic agents suitable for BNCT. To achieve this ambitious goal, the following specific 
objectives were defined: 
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1. To synthesize, functionalize and characterize water soluble and biocompatible AuNPs 
containing PEG and boron-rich clusters with potential application in BNCT. 
2. To evaluate cytotoxicity and cellular uptake of the multifunctionalized AuNPs in relevant 
cancer cell lines. 
3. To develop the radiolabeling strategies for the incorporation of positron emitters in the 
nanoparticles to enable subsequent investigation in vivo using nuclear imaging techniques. 
4. To evaluate stability and pharmacokinetic properties of the novel multifunctionalized AuNPs 
using positron emission tomography (PET) in relevant tumor models. 
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Chapter 3: Gold nanoparticles as boron carriers for BNCT (I) 
3.1. Introduction 
As mentioned in the introductory section of this PhD thesis, boron neutron capture therapy 
(BNCT) is a binary radio-therapeutic modality for the treatment of different types of cancer, 
mainly high grade gliomas and head and neck cancers [1]. Historically, the delivery of a 
sufficient amount of 10B atoms into tumor tissue ((~109 atoms/cell, tumor-to-blood and tumor-to-
normal tissue boron concentration ratios >3), which is paramount for effective BNCT, has been 
one of the main limitations for the unconditional establishment of BNCT in the clinics. Indeed, 
despite decades of effort, only two agents are routinely used in BNCT clinical trials: sodium 
mercaptoundecahydro-closo-dodecaborate (BSH) and L-4-dihydroxyborylphenylalanine (BPA) 
[2]. Additionally, their use is quite limited due to the low tumor-to-blood and tumor-to-healthy 
tissue 10B ratios achieved. As a consequence, there is an urgent need for the development of new 
therapeutic boron delivery systems. 
The hurdle of optimal boron drug delivery has long been recognized in the BNCT community. 
Taking advantage of the recent developments in nanotechnology, different classes of 
nanomaterial-based drug delivery systems have been evaluated and positioned as promising 
boron carriers, as nanosystems can carry a large amount of boron atoms selectively to the tumor 
cells via enhanced permeability retention effect (EPR) (see chapter 1 for more details). 
Surprisingly, despite showing unique physical and chemical properties that include 
biocompatibility, low toxicity, and tunable surface functionalities, gold nanomaterials have been 
barely exploited in this context [3-5].  
Among all gold nanosystems, spherical AuNPs have received considerable interest since their 
successful synthesis was first described in 1951 [6]. Most commonly used spherical AuNPs are in 
the range of few nm to 100 nanometers. Generally, non-PEGylated AuNPs are rapidly uptaken by 
the reticuloendothelial system (RES, currently known as the mononuclear phagocyte system, 
MPS) and are rapidly eliminated from blood circulation to the liver, spleen, lungs or bone 
marrow. Hence, they are not bioavailable anymore and tumor uptake is severely hampered. To 
overcome this problem, most gold nanostructures are functionalized with thiol-terminated 
polyethylene glycol (PEG), which is one of the most commonly used biopolymers to 
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functionalize the surface of AuNPs. Multiple studies have shown that the PEG polymer on 
AuNPs surface increases biological half-life by reducing the opsonization process (Figure 3.1), 
thus preventing uptake by macrophages, allowing the AuNPs to remain in the blood pool and 
accumulate in tumors through passive targeting [7, 8].   
 
 
Figure 3.1. Polyethylene glycol (PEG) prevents uptake by the reticuloendothelial system. (A) 
Nanoparticles (1) are coated with opsonin proteins (2) and associate with macrophages (3) for transit to 
the liver (4). Macrophages stationary in the liver, known as Kupffer cells, also participate in nanoparticle 
scavenging; (B) coating nanoparticles with PEG (1) prevents opsonization (2), resulting in decreased liver 
accumulation (3) and increased availability of the nanoparticles for imaging or therapy (reprinted with 
permission from original source [9]). 
As a first approach for the development of gold NP-based BNCT agents, we decided to work 
with spherical gold particles functionalized with PEG, the latter to achieve prolonged circulation 
time. As a boron source, we decided to incorporate a boron cluster. Indeed, boron clusters such as 
carboranes, metallacarboranes, and other polyhedral boron hydrides have been attached to 
biologically active molecules capable to selectively accumulate in tumor cells [10]. Among the 
different possibilities, we selected the cobalt bis(dicarbollide) anion [3,3´-Co(1,2-C2B9H11)2]– 
(COSAN). COSAN and its derivatives have attracted considerable attention for the development 
of pharmaceutical agents due to their high thermal and chemical stability, rich boron content, and 
low toxicity. Due to their negative charge covering the whole molecule, COSAN derivatives 
exhibit both electrostatic interactions and non-bonding intermolecular interactions between its 
weakly polarized B-H and C-H bonds. Due to this dual nature, COSAN derivatives possess both 
hydrophobic and hydrophilic character, being soluble in both water and oils. These properties, 
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together with its rich derivative chemistry, turn COSAN derivatives into valuable building blocks 
for the preparation of boron-rich drugs with potential application in BNCT. 
In this chapter, we discuss the preparation, characterization and evaluation of size and shape-
tuned gold NPs functionalized simultaneously with Poly(ethylene glycol) methyl ether thiol and 
COSAN. To attach the COSAN cluster to the NPs, thiolated COSAN derivatives were prepared. 
The thiolated group was incorporated into one of the boron atoms of one of the [C2B9H11]2- 
ligands using an inert spacer. Concretely, we prepared the cyclooxonium derivative using 
tetrahydropyran, which was subsequently used to produce the thiolated COSAN derivative, 
which was ultimately attached to PEG-stabilized AuNPs via thiol-gold chemistry. The resulting 
functionalized AuNPs were radiolabeled with 124I to enable in vivo imaging using PET, using two 
different strategies; namely, the radiolabel was incorporated either on the surface of the gold core 
or covalently attached to the COSAN structure. To incorporate the radiolabel on the COSAN 
structure, a new COSAN derivative incorporating one iodine atom directly attached to one of the 
boron atoms of the cluster was synthesized, and successfully radiolabeled with 124I via palladium 
catalyzed iodine exchange reaction. To incorporate the label on the gold core, chemisorption was 
used, as this strategy has proven efficient with other radioisotopes of iodine [11]. Finally, whole 
body imaging studies using Positron Emission Tomography (PET) were carried out in a mouse 
cancer model, generated by subcutaneous inoculation of HT 1080 (human fibrosarcoma) cells, in 
order to assess the in vivo stability of multifunctionalized AuNPs and their capability to 
accumulate in the tumor by passive targeting.  
3.2. Objectives 
The specific objectives of this chapter are: 
1- To synthesize and characterize stable and biocompatible spherical AuNPs functionalized with 
PEG and COSAN.  
2- To perform radiolabeling studies for the incorporation of positron emitters in the core and 
shell of the multifunctionalized AuNPs. 
3- To evaluate pharmacokinetic properties of the novel multifunctionalized AuNPs using 
positron emission tomography (PET) in a human fibrosarcoma mouse tumor model. 
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3.3. Results and discussion 
3.3.1. Synthesis of COSAN derivatives 
The first step for the preparation of the multifunctionalized gold NPs was the development of the 
appropriate COSAN derivatives. First, COSAN derivatives bearing a thiol group were 
synthesized following a previously published methodology [12] with minor modifications 
(Scheme 3.1).  
 
Scheme 3.1. Synthesis of functionalized COSAN derivatives 4.2, [4.3]-, [4.4]-, [4.5]- and [4.6]-. (i) THP, 
dimethylsulphate, H2SO4; (ii) DMF, KSAc; (iii) NaOMe, MeOH; (iv) CH3CN, NaI, Chloramine-T; (v) 
NaOMe, MeOH 
To conduct this reaction, we took advantage of the fact that boron atoms of the cobalt 
bis(dicarbollide) anion possessing high electron density can be easily functionalized with an inert 
spacer. B-substitution is explained by electrophile-induced nucleophilic substitution (EINS) 
mechanism. It involves the abstraction of the B–H hydrogen by an electrophile and subsequent 
attack by the nucleophile present in the reaction mixture. EINS mechanism has been described 
with different nucleophiles, such as tetrahydrofuran, tetrahydropyran and 1,4-dioxane, resulting 
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in the formation of charge-compensated derivatives. In our case, nucleophilic ring opening 
reaction of COSAN derivative (4.2; synthesized as previously described [12]) with potassium 
thioacetate (KSAc) in DMF yielded [4.3]- with overall yield of 52%. The reaction of [4.3]- with 
sodium methoxide in methanol at room temperature yielded [4.4]- in almost quantitative yield.  
In parallel, COSAN derivatives bearing simultaneously a thiol group and an iodine atom were 
also synthesized the latter to enable radiolabeling with the positron emitter 124I before attachment 
to the AuNPs (shell labeling) using isotopic exchange. The incorporation of the iodine atom was 
achieved by reaction of [4.3]- with sodium iodide, chloramine-T and acetic acid in acetonitrile 
overnight at room temperature to yield [4.5]- in 69% yield after purification. Basic hydrolysis of 
[4.5]
- in sodium methoxide and methanol yielded the thio-derivative [4.6]- ready for 
incorporation into NPs or for radiolabeling using isotopic exchange reaction. Characterization 
using 1H-, 11B-, and 13C-NMR confirmed the presence of the desired compounds (see 
experimental section for NMR data and Annex I for NMR spectra). 
3.3.2. Synthesis of functionalized AuNPs 
For successful clinical application, a BNCT drug should deposit a concentration of 10B in the 
tumor in the range 20-35 µg 10B/g of tissue, although lower amounts might be sufficient if the 
boron atoms are internalized into cells [13]. Additionally, high tumor-to-normal tissue and tumor-
to-blood ratios should be achieved in order to prevent damage to healthy tissue and blood 
vasculature during neutron irradiation. Achieving these values is highly challenging, and 
nanotechnology has opened new opportunities due to the well-known EPR effect, which results 
in passive accumulation of nanosized materials in tumor tissue. Here, and inspired by the work 
reported by Cioran et al. [5, 14] we envisaged the possibility of using gold nanoparticles as boron 
carriers. Besides the easy functionalization chemistry, gold nanomaterials are chemically inert 
and non-toxic and both shape and size can be easily tuned [15]. Among all the possibilities, we 
decided to start with spherical particles with a size within the optimal range to achieve tumor 
accumulation [16]. In addition to the boron clusters, we decided to incorporate PEG chains on the 
NP surface in order to enhance the stability of the NPs in biological media and increase 
circulation time. 
AuNPs were prepared by reduction of HAuCl4.3H2O with trisodium citrate following a protocol 
based on the Turkevich method [6]. The aqueous solution of HAuCl4.3H2O was heated to the 
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boiling point while stirring vigorously and then trisodium citrate was added quickly. A color 
change from pale yellow to deep red occurred within 10 minutes, indicating the formation of 
citrate-AuNPs. The solutions were kept at the boiling point for 15 minutes to assure the 
completion of the reaction and finally allowed to cool to room temperature (Figure 3.1). 
 
 
Figure 3.1. Schematic representation of the preparation of citrate-AuNPs and PEG-AuNPs@[4.4]- 
The formation of citrate-AuNPs was confirmed by UV-absorption spectroscopy and transmission 
electron microscopy (TEM). UV-absorption spectra showed the longitudinal surface plasmon 
resonance (SPR) band at 524 nm (Figure 3.2a), indicating the formation of AuNPs with particle 
size in the range of 20 nm. TEM images revealed the presence of non-aggregated citrate-AuNPs 
with average particle size of 19.2±1.4 nm (Figure 3.2c).  
After successful preparation of citrate-AuNPs, the next step was to attach the functionalities, 
namely PEG and COSAN, on the surface of AuNPs. Thiolated polyethylene glycol (mPEG5k-SH) 
and [4.4]- were covalently attached to the surface of the citrate-AuNPs based on a previously 
reported methodology with slight modifications [17]. The ultimate goal was to achieve a 
maximum amount of boron atoms on the surface of the NPs, without compromising stability and 
aggregation status. Hence, we first performed a set of experiments by using various molar ratios 
of PEG and COSAN (1:4, 1:6, 1:8, 1:10, 1:12 and 1:14), which were added to the citrate-AuNPs 
(Au concentration, 1 mg/mL). After addition of PEG and COSAN, the solution was stirred at 
room temperature for 2 h to allow for complete exchange of the citrate molecules with PEG and 
COSAN. The PEG-AuNPs@[4.4]- solutions were then centrifuged and analyzed by ICP-MS to 
investigate the relative amount (PEG to COSAN) for the resulting PEG-AuNPs@[4.4]-. We 
found that, in all cases, NPs were stable and dispersible. However, ratios above 1:10 (PEG to 
COSAN) did not result in an increase in the COSAN concentration on the surface. Under these 
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conditions, the amount of ligand on the surface of the NPs was 200 µg/mg of gold, which results 
in a boron concentration of 90 µg per mg of gold. 
 
Figure 3.2. (a) UV-Vis spectra corresponding to citrate stabilized AuNPs (AuNPs-Citrate, blue, 
λmax=524 nm) and PEG-stabilized AuNPs@[4.4]- (PEG-AuNPs@[4.4]-, red, λmax=531 nm for the gold 
plasmon; λmax=310 nm corresponds to compound [4.4]-); (b) Size distribution ranges as determined by 
DLS (volume distribution) for AuNPs-Citrate and PEG-AuNPs@[4.4]- (same color code as in (a)); (c) 
representative TEM images of AuNPs-Citrate and PEG-AuNPs@[4.4]-; (d) Particle size distribution of 
PEG-AuNPs@[4.4]- as determined by TEM. 
The characterization of the final particles PEG-AuNPs@[4.4]- was carried out first using UV-vis 
spectrophotometry (Figure 3.2a). As it can be seen, the simultaneous incorporation of PEG and 
COSAN on the surface of the citrate AuNPs resulted in a bathochromic shift in the longitudinal 
surface plasmon resonance (SPR) band from 524 nm to 531 nm. Noteworthy, another absorption 
band appeared at ca. 310 nm, close to the maximum absorption of COSAN (314 nm), confirming 
successful incorporation of the boron cluster on the surface of the AuNPs. 





Figure 3.3. Raman spectra for PEG-AuNPs@[4.4]- (blue) and [4.4]- (red), (b) XPS spectra of PEG-
AuNPs@[4.4]-. 
Dynamic light scattering (DLS) analysis performed on citrate-AuNPs and PEG-AuNPs@[4.4]- 
showed a monodisperse distribution with average hydrodynamic diameter of 24.4±0.5 nm and 
37.8±0.5 nm respectively (Figure 3.2b). The increase in hydrodynamic size from 24.4±0.5 nm 
and 37.8±0.5 nm is largely due to the addition of PEG molecule, as the small size of the COSAN 
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moiety (~ 1-2 nm) is expected to have a minimal impact on hydrodynamic size when compared 
to the effect of the large molecule PEG-5000. Transmission electron microscopy (TEM) images 
show non-aggregated spherical AuNPs before and after PEG and COSAN addition (Figure 3.2c) 
with average particle core size of 19.2±1.4 nm (Figure 3.2d). Zeta potential measurements of 
citrate-AuNPs showed a ξ-potential of −32.3±2.5 mV; after incorporation of both PEG and 
COSAN, PEG-AuNPs@[4.4]- showed a ξ-potential value of −18.0±0.7 mV at neutral pH, the 
negative value due to the presence of COSAN anions on the surface of the NPs. 
To further confirm the presence of COSAN moieties on the surface of the AuNPs, we performed 
Raman spectroscopy and X-ray photoelectron spectroscopy (XPS). The Raman spectra of PEG-
AuNPs@[4.4]- showed the presence of absorption bands at 2596−2573 cm−1, corresponding to 
B−H stretching and confirming the presence of the sandwich complex on the NP surface (Figure 
3.3a). Finally, XPS analysis of PEG-AuNPs@[4.4]- showed a peak at 780.2 eV in the Co 
spectrum, corresponding to Co-B bonds; peaks at 192.8 and 188.5 eV, corresponding to B-O and 
C-B bonds; peaks at 87.5 and 83.5 eV, corresponding to Au; and a peak at 162.5 eV, 
corresponding to Au-S-C bond (Figure 3.3b) [18]. These results confirmed the presence of both 
cobalt and boron on the surface of AuNPs; altogether, our results confirm that the NPs have a 
significant boron load and appropriate size for eventual tumor accumulation. 
3.3.3. Radiolabeling of AuNPs 
One of the main challenges in BNCT is the determination of the biodistribution of the boron 
carrier after administration, in order to establish the optimal time window for neutron irradiation, 
for the therapeutic effect to be optimal, while minimizing side effects and destruction of the 
surrounding healthy tissue (Figure 3.4). This drawback is even more evident when nanomaterials 
are used as boron carriers, as the determination of the biodistribution and fate of NPs after 
administration into living systems is extremely challenging. One alternative to overcome this 
drawback consists of incorporating a positron or gamma emitter into the nanoparticle in order to 
track the location in a time-resolved fashion using Positron Emission Tomography (PET) or 
Single Photon Emission Computerized Tomography (SPECT) imaging. This approach has been 
widely reported in the literature in NPs with very different nature [19, 20]. Additionally, 
incorporation of the label both at the core and at the shell of NPs can provide very relevant 
information about the in vivo stability of the NPs [21]. 





Figure 3.4. Fictitious boron concentration curves vs. time for the tumor (blue), blood (red) and healthy 
tissue (green). The optimal time-window for the application of neutron irradiation, when the concentration 
of boron is maximum in the tumor and low in both blood and healthy tissue, is shown. 
Here, we decided to tackle the radiolabeling of the NPs using a positron emitter, as PET offers 
better spatiotemporal resolution and higher resolution than SPECT. We anticipated that the 
positron emitter 124I (half-life of 4.2 days) was appropriate due to the following reasons: (i) its 
reasonably long half-life should enable long-term monitoring (up to 2 weeks if needed) of the in 
vivo behavior of the NPs; (ii) due to the versatile chemistry of the radionuclide, it could be 
incorporated both at the core, taking advantage of the capacity of iodine to absorb onto gold 
surfaces [11], and on the shell, by generating first a iodinated analogue of COSAN and 
performing in a second step isotopic exchange reaction, as previously described [22]. Our 
hypothesis is that the iodinated analogue of COSAN should behave quite similarly to the non-
iodinated counterpart, and hence the properties of the AuNPs should not be significantly altered 
by the incorporation of the label.  
We first tackled the incorporation of 124I at the shell (Figure 3.5). With that aim, compound 124I-
[4.5]
- was prepared by isotopic exchange, following a methodology previously described in our 
group with minor modifications (Scheme 3.2) [22]. In brief, acetonitrile was added to Na[124I]I 
(obtained from the supplier as a solution in diluted NaOH) and the resulting solution was 
evaporated to dryness under nitrogen flow. Compound [4.5]- was dissolved in acetonitrile was 
added to the dry residue, together with trans-bis(acetate)bis[o-(di-o-tolylphosphino)benzyl] 
dipalladium (II) (Herrmann’s catalyst), the later dissolved in toluene. The reaction mixture was 
heated at 100°C for 5 min, the solvent was removed under a constant helium flow and the 
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resulting solid was dissolved in acetonitrile and water. The crude solution was passed through a 
C-18 cartridge (Sep-Pak® Light, Waters) and washed with ultrapure water to remove free iodine-
124. The labeled compound, retained in the C-18 cartridge, was finally eluted with acetonitrile, 
which was finally evaporated to yield the labeled compound as an orange solid. 
 
Figure 3.5. Schematic representation for the preparation of shell radiolabeled PEG-AuNPs@[4.4]-. [i] 
PEG-SH (5 Kda), 124I-[4.6]- + [4.4]-. 
 
 
Scheme 3.2. Reaction for the preparation of 124I-[4.6]- 
Quality control was performed by high performance liquid chromatography (HPLC) coupled to a 
radioactivity detector. With that aim, the solid residue was diluted with mobile phase (see 
experimental section for details) and analyzed. Incorporation ratios of the radiolabel (measured 
directly from chromatographic profiles, radioactivity detector) of 69±6% were achieved when the 
reaction was conducted at 100°C for 5 min. These values are in good agreement with those 
previously described [22]. Purification by semi-preparative HPLC resulted in a solution of 
chemically and radiochemically pure compound 124I-[4.5]- (Figure 3.6) with radiochemical yield 
(non-decay corrected) of ca. 60%.  




Figure 3.6. Chromatographic profiles (UV and radiometric detection) for reference compound [4.5]- (top) 
and purified 124I-[4.5]- (bottom). The difference in the position of the two peaks is due to the dead volume 
between the UV and the radioactivity detectors.  
The isotopic exchange reaction was carried out using [4.5]-, which had the thiol group protected, 
because the presence of a free thiol group may interfere in the isotopic exchange reaction. Hence, 
to enable attachment of the labeled COSAN analogue to the gold NPs, deprotection was required. 
With that aim, 124I-[4.5]- was reacted with sodium methoxide in methanol at room temperature 
for 6 h, yielding 124I-[4.6]- in quantitative yield, which was used without further purification. The 
preparation of the radiolabeled AuNPs was carried out following the same process described 
above, but compound [4.4]- was spiked with 124I-[4.6]-. Radiolabeling efficiency, calculated as 
the amount of radioactivity present in the NPs related to the starting amount of 124I-[4.6]- was 
55%.  
The second approach for the preparation of radiolabeled AuNPs was based on the absorption of 
radioiodine on the surface of the gold core [11, 23]. First, we tried to incorporate radioiodine 
directly on PEG-AuNPs@[4.4]- (Figure 3.7). However, low incorporation efficiencies (<10%) 
were achieved when PEG-AuNPs@[4.4]- were incubated with the radionuclide. These results are 
not in agreement with previously reported works, in which almost quantitative labeling yields 
were obtained [11, 23]. We suspected that the presence of the COSAN anions on the surface of 
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the NPs hampered the adsorption of radioiodide on the gold surface, probably due to electrostatic 
repulsion or steric hindrance. 
  
Figure 3.7. Schematic representation for the preparation of core radiolabeled PEG-AuNPs@[4.4]-. [i] 
PEG-SH (5 Kda), [4.4]-, [ii] [124I]NaI.  
To overcome this limitation, we assayed a second strategy, based on the incorporation of the 
radionuclide on citrate-stabilized NPs, which were functionalized with PEG and COSAN 
derivatives in a second step.  
 
Figure 3.8. Schematic representation for the preparation of core radiolabeled PEG-AuNPs@[4.4]-. [i] 
[124I]NaI; (ii) PEG-SH (5 Kda), 124I-[4.6]- + [4.4]-.  
With that aim, citrate-stabilized NPs were incubated with radioiodine and incorporation ratios 
were determined at different incubation times. Experimental results demonstrated that the 
reaction took place very rapidly, as incorporation ratios >95% were achieved in just 10 minutes 
of incubation. These results are more in line with those previously reported in the literature. In 
view of these results, we decided to incorporate the radiolabel on citrate-stabilized NPs and 
incorporate both the PEG and COSAN derivatives in a second step (Figure 3.8). This approach 
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was successful and core-labeled NPs with size and zeta-potential values equivalent to those 
obtained for non-labeled NPs could be determined using DLS.   
3.3.4. Radiochemical stability of AuNPs 
One of the main limitations of the second labeling approach is the risk of detachment of the 
absorbed radionuclide. Ideally, radiochemical stability of the labeled particles should be 
evaluated in vivo. However, this is extremely challenging. An alternative approach consists of 
incubating the labeled particles in different media, trying to mimic in vivo conditions [24]. In our 
case, in order to evaluate the radiochemical stability of core-labeled [124I]PEG-AuNPs@[4.4]-, 
NPs were incubated in different media, including water, saline, PBS (10 mM), DMEM (Cell 
culture media), plasma and potassium iodide (10 µM).  
 
Figure 3.9. Radiochemical stability of core-labeled PEG-AuNPs@[4.4]- in different media for 24 h; 
Water; NaCl: physiologic saline solution (0.9%); PBS (10 mM); DMEM: Culture media, cocktail of 8 
salts, 15 amino acids, 8 vitamins and glucose;  KI: potassium iodide solution (10 µM). 
After incubation at 37 °C for 24 h, the NPs were separated from the media by centrifugal 
filtration and washed three times, and the radiochemical stability was determined as the ratio 
between the amount of radioactivity in the NPs and the total amount of radioactivity (NPs + 
media + washings). Good radiochemical stability (>90%) was observed in all media except 
potassium iodide (Figure 3.9), thus confirming the chemisorption of 124I and the suitability of the 
labeling strategy for in vivo studies.  
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3.3.5.  Biodistribution studies in tumor bearing animals 
The capacity of the newly developed AuNPs (PEG-AuNPs@[4.4]-) to accumulate in tumor tissue 
was investigated in a subcutaneous mouse model generated by inoculation of HT 1080 cells in 
nude mice. Traditionally, BNCT has been investigated mainly for brain (gliomas) and head & 
neck cancers. However, this therapeutic approach can in principle be evaluated in any cancer 
type, and those cancers with high mortality or lack of efficient therapeutic alternatives are worth 
to be assayed. Hence, we decided to investigate human fibrosarcoma tumor model. This is a quite 
rare cancer type. However, it is highly aggressive and metastasizes at early stages. The standard 
therapy, which includes surgical resection and adjuvant chemotherapy, is ineffective due to local 
recurrence and distant metastasis [25]. 
Imaging studies performed in mice enabled the determination of the biodistribution pattern of the 
labeled particles. Additionally, the inclusion of the label in the two different positions (the core 
and the shell) was used to gain information about the stability of the core-shell structure, an issue 
that is rarely tackled in preclinical in vivo investigations. With that aim, animals were injected 
with the labeled particles and images were acquired immediately after administration (total 
acquisition time of 60 min). Additionally, 30 min static acquisitions were recorded also at t=10, 
24, 72 and 144 h post-administration (Figure 3.10).  
Visual inspection of the images showed a similar biodistribution pattern for both PEG-
AuNPs@[4.4]-, irrespectively of the position of the label. High accumulation was observed in the 
liver at short times after administration (0-1 hour). Delineation of volumes of interest (VOIs) in 
major organs (lungs, liver, bladder, stomach, kidneys, spleen, tumor, heart and thyroid gland) and 
determination of the uptake as % of injected dose per cm3 tissue (%ID/cm3, see Figure 3.11) 
revealed similar profiles irrespective of the position of the label, this confirming the in vivo 
stability of the core-shell structure. Major accumulation at short times after administration was 
observed in the liver. For this organ, values at the first time point were 42.2 ± 4.8 and 39.1 ± 5.8 
%ID/cm3 for core and shell labeled particles, respectively. These values, which are statistically 
equivalent, progressively decreased with time to reach values close to 10% ID/cm3 at t=144 h. 
Accumulation in the stomach peaked at t=24 h after administration, with progressive elimination 
from this organ at later time points. Accumulation in the lungs was also significant. Of note, the 
detection of radioactivity in the heart reflects the presence of labeled NPs in the bloodstream, 
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even at long times after administration. The presence of radioactivity in the bladder at long times 
after administration confirms slow elimination via urine. This result, together with the detection 
of radioactive signal in the thyroid gland, suggests the progressive (although very slow) 
detachment of the radiolabel in both cases (core and shell labeling). 




















Figure 3.10. PET images (coronal projections) obtained at different time points after intravenous 
administration of [124I]PEG-AuNPs@[4.4]- labeled at the core and at the shell. PET images have been 
corregistered with representative CT slices for localization of the radioactive signal. The image labeled as 
“0-1 hour” corresponds to the image obtained immediately after administration of the labelled NPs 
(imaging time = 1 hour).    
Our biodistribution data, in general terms, correlates well with previous results obtained with 
negatively charged NPs. In general, it has been found that, upon single intravenous 
administration, spherical AuNPs localize in liver, kidneys, spleen and lungs, with this 
phenomenon being size- and shape-dependent. For NPs in our size range, major accumulation 
should be expected in liver, spleen and lungs, as observed in our studies [26]. 




Figure 3.11. Concentration of radioactivity in the different organs as determined from PET images using 
the two radiolabeling approaches. Values are expressed as %ID/cm3. Values correspond to mean ± 
standard deviation, n=2 per labeling strategy and time point.    
Next, we conducted ex vivo analysis to confirm the NPs accumulation in the liver observed 
during in vivo studies. With that aim, after the last imaging session, animals were sacrificed and 
the liver organ was collected and investigated using ion beam microscopy (IBM) and confocal 
Raman microspectroscopy (CRM) (Figure 3.12). These label-free techniques have proven to be 
efficient for simultaneous quantification and visualization of a variety of NPs in biological 
environments [27, 28, 29, 30, 31]. The µPIXE spectrum extracted from the region of interest 
(ROI; see Figure 3.12b) reveals X-ray emission of intrinsic tissues elements, i.e., P, S, Ca etc., as 
well as of gold. Characteristic Lα, Lβ and Lγ X-ray lines of gold at 9.7 keV, 11.4 keV and 13.4 
keV were detected in the ROIs shown as green regions in Figure 3.12a. The structure of several 
connected hepatic lobules could be identified due to P and S distribution in the PIXE images. 
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PIXE maps of Au distribution showed a rather homogenous distribution all over those lobules. 
However, a high resolution image with a size of 100 × 100 µm revealed small gold clusters in the 
hepatocytes (white circles in Figure 3.12a). 
 
 
Figure 3.12. (a) µPIXE images of intrinsic tissue elements (P, S, Fe) as well as Au in mouse liver at t = 72 
h after intravenous administration of [124I]PEG-AuNPs@[4]−. The area in the white rectangle was 
subsequently scanned with higher resolution. The concentration of elements was calculated from regions 
of interest (ROIs) shown in green on the right side. White arrows denote hepatic lobules. White circles 
show small gold clusters; (b) PIXE spectrum extracted from ROIs; (c) CRM images of hepatocytes and 
distribution of [124I]PEG-AuNPs@[4]− in in mouse liver at t = 72 h after intravenous administration of 
[124I]PEG-AuNPs@[4]−. The color-coded image (left) shows the overlapping of nucleus, cytoplasm, 
collagen and COSAN- functionalized Au NPs. 
CRM imaging was additionally used to visualize the distribution pattern of NPs in the liver at 
subcellular level (Figure 3.12c). Au NPs were localized in hepatic lobules by using 
photoluminescence signals of Au. Cytoplasm, nuclei and collagen were visualized on the basis of 
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Raman fingerprint regions of biomolecules [32, 33, 34], which are predominantly present in the 
corresponding constituents of cell. As it can be seen, lobules are surrounded by supporting 
connective tissue, which was identified in CRM imaging by the presence of collagen. Au NPs 
were found in the cytoplasm of hepatocytes as well as in close vicinity to their nuclei. Some Au 
NP aggregates were also detected between adjacent lobules showing a co-localization with the 
connective tissue. 
The data obtained in our in vivo study confirm that the position of the label does not have an 
effect on the biodistribution of the NPs, hence confirming that the label is relatively stable in 
vivo. However, the high uptake in the liver already at early times after administration of the NPs 
compromises the usefulness of our nanosystems for in vivo applications. The high uptake in the 
liver results in a low bioavailability, and as a consequence the circulation time is low and the 
tumor accumulation is almost negligible, with values below 0.5% ID/cm3, irrespective of the 
labeling approach and time point. Considering that the boron load of our NPs is ca. 9% and that 
the administered dose of NPs was 150 µg (ca. 7.5 mg NP/Kg body weight; 0.675 mg B/Kg body 
weight), the boron accumulation in the tumor is close to 0.06 µg B/g of tumor. This value is by 
far too low to plan any therapeutic experiments. The results demand for modifications in the 
physic-chemical properties of the NPs in order to improve pharmacokinetic properties, which 
ultimately may lead to increased accumulation in the tumor. This was carried out as described in 
the following chapters. 
3.4. Conclusions 
The reaction of citrate-stabilized gold NPs with COSAN bearing a thiol moiety and thiolated 
polyethylene glycol (mPEG5k-SH) yields NPs with ca. 9% boron content on the surface. 
Radiolabeling of the NPs with the positron emitter 124I could be achieved both at the core (by 
absorption of 124I on the gold surface) or at the shell (by using isotopic exchange). The labeled 
particles showed good stability both in vitro and in vivo, although progressive detachment of the 
label could be observed in vivo. Investigation of the biodistribution pattern in a mouse cancer 
model using positron emission tomography confirmed high accumulation of the NPs in the liver 
at short times after administration, and very low accumulation in the tumor, the latter demanding 
for modification in the physico-chemical properties of the NPs in order to achieve higher tumor 
uptake.  
Chapter 3 – GNPs as boron carriers for BNCT (I) 
48 
 
3.5. Experimental section  
3.5.1. Reagents 
Cesium cobalt(III) bis(dicarbollide) (COSAN) (Katchem Ltd., Prague, Czech Republic), gold(III) 
chloride trihydrate (HAuCl4·3H2O, Aldrich), sodium citrate tribasic dihydrate (Sigma-Aldrich), 
poly (ethylene glycol) methyl ether thiol (MW 5000, Sigma-Aldrich) tetrahydropyran (Sigma-
Aldrich) and trans-bis(acetate)bis[o-(di-o-tolylphosphino)benzyl] dipalladium (II) (Herrmann’s 
catalyst, Sigma-Aldrich), were used as purchased. All other reagents and anhydrous solvents, 
stored over 4 Å molecular sieves, were purchased from Aldrich Chemical Co. (Madrid, Spain) 
and used without further purification. HPLC grade solvents were purchased from Scharlab 
(Sentmenat, Barcelona, Spain). For radiolabeling experiments, Iodine-124 (124I) was obtained 
from PerkinElmer. (Le petten, The Netherlands) in 0.2 M NaOH solution. 
In chemical reactions, experiments were carried out (except noted otherwise), under dinitrogen 
atmosphere. Column chromatography was performed using silica gel 60 (Scharlab, Spain). 
Analytical thin layer chromatography (TLC) measurements were conducted with silica gel 60 
F254 plates (Macherey-Nagel); and the spots were visualized under UV lamp. Synthesis of 
compound 4.2 was carried out according to the previously reported protocol [12]. 
3.5.2. Instrumentation 
The 1H-NMR (500 MHz), 13C-NMR (126 MHz) and 11B-NMR (160 MHz) spectra were recorded 
on a 500-MHz Avance III Bruker spectrometer. All NMR spectra were performed in deuterated 
solvents at 22°C. The 11B-NMR shifts were referenced to external BF3·OEt2, while the 1H and 
13C-NMR shifts were referenced to SiMe4. Chemical shifts are reported in units of parts per 
million downfield from the reference, and all coupling constants are reported in Hertz.  
UPLC/ESI-MS analyses were performed using an AQUITY UPLC separation module coupled to 
a LCT TOF Premier XE mass spectrometer (Waters, Manchester, UK), using an Acquity BEH 
C18 column (1.7 µm, 5 mm, 2.1 mm) as the stationary phase. The elution buffers were A (water 
and 0.1% formic acid) and B (Methanol and 0.1% formic acid). The column was eluted with a 
gradient: t=0 min, 95% A, 5% B; t=0.5 min, 95% A, 5% B; t=5.5 min, 25% A, 75% B; t=16 min, 
1% A, 99% B;  t=20min, 1% A, 99% B. Total run was 20 min, injection volume was 5 µL and 
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the flow rate 300 µL/min. The detection was carried out in both negative and positive ion mode, 
monitoring the most abundant isotope peaks from the mass spectra (M-H+) or (M+H+). 
Transmission electron microscopy (TEM) was performed using a JEOL JEM-1400 plus 
microscope (Jeol, Tokyo, Japan) working at 120 kV. The carbon film of copper grids (CF400-
Cu) was treated under air plasma in a glow discharge system (Emitech K100X, 40mA during 2 
min) just before sample preparation. For TEM examinations, a single drop (1 μL) of the NPs 
solution was placed onto a copper grid coated with a carbon film (Electron Microscopy 
Sciences). After 1 minute, the drop was removed with filter paper and the sample was incubated 
with 3 μL of uranyl acetate 0.5% (3 min). 
XPS experiments were performed in a SPECS Sage HR 100 spectrometer with a non-
monochromatic X ray source (Aluminium Kα line of 1486.6 eV energy and 252 W), placed 
perpendicular to the analyser axis and calibrated using the 3d5/2 line of Ag with a full width at 
half maximum (FWHM) of 1.1 eV. The selected resolution for the spectra was 15 eV of Pass 
Energy and 0.15 eV/step. All measurements were made in an ultra-high vacuum (UHV) chamber 
at a pressure around 6×10-8 mbar. An electron flood gun was used for charge neutralisation. 
Gaussian Lorentzian functions were used for fittings (after a Shirley background correction) 
where the FWHM of all the peaks were constrained while the peak positions and areas were set 
free. Main C1s peak was used for charge reference and set at 284.8 eV. 
ICP-MS measurements were performed on a Thermo iCAP Q ICP-MS (Thermo Fisher Scientific 
GmbH, Bremen, Germany). An ASX-560 autosampler was coupled to the ICP-MS (CETAC 
Tech, Omaha, NE, USA). UV-Vis spectra were measured in an Agilent 8453 UV-Vis diode-array 
spectrophotometer. DLS and ξ-potential measurements were performed using a Malvern 
Zetasizer Nano ZS system (Malvern Instruments, Malvern, UK). The particle size measurement 
settings were: 3 measurements/14 runs/10s in scattered mode at 173° angle. Measurements were 
conducted at T=25°C and neutral pH. 
Raman characterization was performed with a Renishaw InVia Raman Microscope. A 633 nm 
laser (50 % power) was used with 10x objective.  




Synthesis of [4.3]-  
To a solution of compound 4.2 (750 mg, 1.209 mmol) in DMF (8 mL), potassium thioacetate 
(165.7 mg, 1.451 mmol) was added and stirred at room temperature for 14 h. After finalization of 
the reaction, water (50 mL) was added and extracted with ethyl acetate (3x50 mL). The organic 
layers were combined and washed with cold water and brine solution before drying over 
anhydrous sodium sulphate. The solvent was evaporated and the crude was purified using column 
chromatography (silica gel, 10% MeOH in dichloromethane) to yield a [4.3]- as yellow solid (705 
mg, 84%).  
1H NMR (500 MHz, Methanol-d4) δ 4.15 [Cc–H, 2H, s], 4.07 [Cc–H, 2H, s], 3.49 [CH2O, 2 H, t], 
2.87 [CH2-S, 2 H, t], 2.31 [CH3, 3 H, s], 1.59 – 1.54 [CH2-CH2-O, 2 H, m], 1.52 – 1.47 [CH2-
CH2S, 2 H, m], 1.42 – 1.37 [CH2-CH2CH2O, 2 H, m]; 11B NMR (160 MHz, MeOD) δ 23.03[1B, 
s], 4.63 [1B, d, 1J(B-H)=140.3], 0.48 [1B, d, 1J(B-H)=143.3], -2.10 [1B, d, 1J(B-H)=142.8], -
4.59[2B, d, 1J(B-H)=138.7], -8.46 [6B, td, J 162.8, 150.9, 63.5], -17.22 [2B, d, 1J(B-H)=154.4], -
20.42 [2B, d], -22.59 [1B, d], -28.26 [1B, d, 1J(B-H)=159.4]; 13C NMR (126 MHz, Methanol-d4): 
188.24, 68.93, 53.54, 46.70, 30.89, 29.21, 29.14, 28.61, 25.10; LCMS (ESI) Experimental [M]-  
m/z = 482.66 (theoretical [M]- m/z = 482.98). 
Synthesis of [4.4]-  
To a solution of [4.3]- (890 mg, 1.440 mmol) in methanol (30 mL), sodium methoxide (77.8 mg, 
1.440 mmol) was added and stirred at room temperature for 14 h. The reaction mixture was 
neutralized with IR-120 resin (3g), filtered and washed with 10 mL of methanol. The combined 
methanol layers were concentrated and purified using column chromatography (silica gel, 12% 
MeOH in dichloromethane) to yield [4.4]- as a yellow solid (505 mg, 60.5%).  
1H NMR (500 MHz, MeOD) δ 4.14 [Cc–H, 2H, bs], 4.06 [Cc–H, 2H, bs], 3.51 [CH2O, 2 H, t], 
2.50 [CH2-S, 2 H, t], 1.60 [CH2-CH2-O, 2 H, p], 1.58, 1.53 [CH2-CH2S, 2 H, dq], 1.42 [CH2-
CH2CH2O, 2 H, qd]; 11B NMR (160 MHz, MeOD) δ 23.02 [1B, s], 4.64 [1B, d, 1J(B-H)=140.0], 
0.52 [1B, d, 1J(B-H)=142.0], -2.11 [1B, d, 1J(B-H)=144.5], -4.56 [2B, d, 1J(B-H)=142.4], -7.41 
[6B, m], -17.20 [2B, d, 1J(B-H)=157.7], -20.46 [2B, d, 1J(B-H)=159.0], -22.05 [1B, d], -28.22 
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[1B, d, 1J(B-H)=174.3]; 13C NMR (126 MHz, MeOD) δ 69.08, 53.46, 46.70, 33.90, 30.83, 24.71, 
23.65. LCMS (ESI) Experimental [M]-  m/z = 440.52 (theoretical [M]- m/z = 440.94). 
Synthesis of [4.5]- 
To a solution of [4.3]- (50 mg, 0.081 mmol) in acetonitrile (2 mL), chloramine-T (37 mg, 0.129 
mmol), sodium iodide (15 mg, 0.097 mmol) and acetic acid (130 μL) were added. The reaction 
mixture was allowed to stir at room temperature for 10 h. After reaction, water (20 mL) was 
added and extracted with ethyl acetate (3x15 mL), the organic layers were combined and washed 
with brine solution before drying over anhydrous sodium sulphate. The solvent was evaporated 
and the crude was purified using column chromatography (silica gel, 10% MeOH in 
dichloromethane) to yield [4.5]- as a yellow solid (25 mg, 41.6%).  
1H NMR (500 MHz, MeOD) δ 4.27 [Cc–H, 2H, s], 4.13 [Cc–H, 2H, s], 3.37 [CH2O, 2 H, t], 2.85 
[CH2-S, 2 H, t], 2.31 [CH3, 3 H, s], 1.55 [CH2-CH2-O, 2 H, m], 1.45 [CH2-CH2S, 2 H, m], 1.36 
[CH2-CH2CH2O, 2 H, m]; 11B NMR (160 MHz, MeOD) δ 21.47 [1B, s], -0.42[2B, d, 1J(B-
H)=145.4], -4.39 [1B, s], -5.71 [4B, d, 1J(B-H)=140.0], -7.27 [4B, d, 1J(B-H)=152.8], -18.07 [2B, 
d, 1J(B-H)=152.4], -20.04 [2B, d, 1J(B-H)=161.3], -23.45 [1B, d, 1J(B-H)=161.3], -27.37 [1B, d, 
1J(B-H)=170.4]; 13C NMR (126 MHz, CDCl3) δ 191.05, 70.24, 58.99, 56.52, 34.78, 33.10, 32.97, 
32.52, 29.24. LCMS (ESI) Experimental [M]- m/z = 606.6 (theoretical [M]- m/z = 607.6). 
Synthesis of [4.6]- 
To a solution of [4.5]- (9 mg, 0.0144 mmol) in methanol (3 mL), sodium methoxide (1 mg, 
0.0144 mmol) was added and the resulting solution was allowed to stir at room temperature for 
14 h. For the workup, the reaction mixture was neutralized with IR-120 resin (100 mg), filtered 
and washed with 2 mL of methanol. The combined methanol layer was concentrated and the 
residue was purified using column chromatography (silica gel, 12% MeOH in dichloromethane) 
to yield [4.6]- as a yellow solid (4.5 mg, 55%). 
1H NMR (500 MHz, MeOD) δ 4.28 [Cc–H, 2H, s], 4.14 [Cc–H, 2H, s], 3.40 [CH2O, 2 H, t],  2.67 
[CH2-S, 2 H, t], 1.66 [CH2-CH2-O, 2 H, m], 1.46 [CH2-CH2S, 2 H, q], 1.38 [CH2-CH2CH2O, 2 H, 
m]; 11B NMR (160 MHz, MeOD) δ 21.55 [1B, s], -0.34 [2B, d, 1J(B-H)=146.7], -4.32 [1B, s], -
5.57 [4B, d, 1J(B-H)=170.0], -6.90 [4B, d], -17.94 [2B, d, 1J(B-H)=167.3], -20.58  [2B, d, 1J(B-
H)=153.2], -23.13 [2B, d, 1J(B-H)=266.4], -26.79 [2B, d]; 13C NMR (126 MHz, MeOD) δ 68.68, 
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56.57, 53.91, 38.38, 31.04, 28.70, 24.81. LCMS (ESI) Experimental [M]- m/z = 566.64 
(theoretical [M]- m/z = 566.84). 
3.5.4. Radiochemistry 
The manipulation of radioactive material was carried out in authorised facilities and using the 
common and personnel protection equipment as described in internal protocols and following 
current national and international regulations.  
Synthesis of 124I-[4.5]-  
Acetonitrile (200μL) was added to Na[124I]I (50 µL, 37 MBq) and the resulting solution was 
introduced in a 2.5 mL conic vial. The solvent was evaporated to dryness (100°C, 5 min, constant 
helium flow at 20 mL/min) and 1 mg of [4.5]- dissolved in acetonitrile (100 μL) was added 
together with trans-bis(acetate)bis[o-(di-o-tolylphosphino)benzyl] dipalladium (II) (Herrmann’s 
catalyst, HC, 0.1 mg, 0.101 μmol) dissolved in toluene (100 µL). The reaction mixture was 
heated at 100°C for 5 min, the solvent was removed under a constant helium flow and the 
resulting solid was dissolved in 0.5 mL acetonitrile and 30 mL of ultrapure water. The crude 
solution was passed through a C-18 cartridge (Sep-Pak® Light, Waters) and washed with water 
(5 mL × 2) to remove free iodine-124. The final product (124I-[4.5]-), retained in the C-18 
cartridge, was eluted with ethanol (500 μL). The solvent was finally evaporated to dryness. 
Quality control was performed by radio-HPLC after diluting the solid residue with mobile phase. 
Analytical conditions were: Stationary phase: Mediterranea Sea18 column (4.6x150 mm, 5 μm 
particle size, Teknokroma, Spain); mobile phase A: 0.1M ammonium formate (AMF) buffer pH= 
3.9; B: acetonitrile; flow rate = 1mL/min; gradient: 0 min: 60% A- 40% B; 2min: 60% A- 40% 
B; 6min: 20% A- 80% B; 14min: 0% A- 100% B; 16min: 0% A- 100% B; 18min: 60% A- 40% 
B; 20min: 60% A- 40% B (retention time: 11.5min).  
Synthesis of 124I-[4.6]-  
Dry 124I-[4.5]- obtained from the previous step was dissolved in 250 μL of methanol. Sodium 
methoxide (2 mg) was added and stirred at room temperature for 6 h. After Completion of the 
hydrolysis, confirmed by analytical radio-HPLC, reformulation was carried out by dilution with 
water, retention on a C-18 cartridge (Sep-Pak® Light, Waters), further elution with ethanol (500 
μL, Sigma-Aldrich) and evaporation to dryness. Quality control was performed by HPLC. 
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Analytical conditions were: Stationary phase: Mediterranea Sea18 column (4.6x150 mm, 5 μm 
particle size, Teknokroma, Spain); mobile phase A: 0.1M ammonium formate (AMF) buffer pH= 
3.9; B: acetonitrile; flow rate = 1mL/min; gradient: 0 min: 60% A- 40% B; 2min: 60% A- 40% 
B; 6min: 20% A- 80% B; 14min: 0% A- 100% B; 16min: 0% A- 100% B; 18min: 60% A- 40% 
B; 20min: 60% A- 40% B (retention time: 13.1min). 
3.5.5. Preparation of AuNPs 
Synthesis of citrate-stabilized gold NPs (CIT-AuNPs) 
CIT-AuNPs with an average diameter of 18-20 nm and with Au concentration of 1 mg/mL were 
synthesized following the Turkevich method [6]. In brief, 97.1 mg (0.33 mmol) trisodium citrate 
dihydrate were dissolved in 150 mL water (concentration = 2.2 mM) and the solution was heated 
to reflux in a 250 mL three-necked flask equipped with a Dimroth condenser. After 15 min 
boiling, 1 mL precursor solution (HAuCl4∙3H2O in water, 25 mM) was quickly injected under 
rapid stirring. When the colour of the solution changed to the characteristic wine-red, which 
indicates formation of AuNPs, the heating-mantle was switched off but not removed until the 
temperature of the solution was 70 °C. The resulting NPs were centrifuged at 12000g for 20 min 
to remove free citrate and resuspended in ultrapure water. 
Synthesis of PEG-stabilized, COSAN-functionalized AuNPs (PEG-AuNPs@[4.4]-) 
CIT-AuNPs prepared as described above (2 mL) were placed into a vial. Then 100 μL of 
mPEG5k-SH (3 mg/mL) were slowly added under vigorous stirring. After 15 minutes, 100 μL of a 
fresh solution of [4.4]- in ethanol (3 mg/mL) were quickly added and stirring was maintained for 
2h. The resulting NPs were centrifuged at 12000g for 25 min and resuspended in ultrapure water 
three times. 
Synthesis of PEG-AuNPs@[4.4]- labeled at the core  
CIT-AuNPs prepared as described above (2 mL) were placed into a vial. [124I]NaI (15 μL, 
solution in 0.1M NaOH) was added and the solution was stirred for 10 min. Then, mPEG5k-SH 
(100 μL, 3 mg/mL) was slowly added under vigorous stirring. After 15 minutes, 100 μL of a 
fresh solution of [4.4]- in ethanol (3 mg/mL) were quickly added and stirring was maintained for 
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2h. The resulting NPs were centrifuged at 12000g for 25 min and resuspended in ultrapure water 
three times.  
Synthesis of PEG-stabilized, COSAN-functionalized AuNPs labeled at the shell  
CIT-AuNPs prepared as described above (1 mL) were placed into a vial. Then, mPEG5k-SH (100 
μL, 3 mg/mL) was slowly added under vigorous stirring. After 15 minutes, 100 μL of a fresh 
solution of [4.4]- in ethanol (3 mg/mL) and freshly prepared 124I-[4.6]- (22.2 MBq) dissolved in 
ethanol (15 μL) were quickly added and stirring was maintained for 2h. The resulting NPs were 
centrifuged at 12000g for 25 min and resuspended in ultrapure water three times.  
3.5.6. In vivo experiments 
Animals 
The animals were maintained and handled in accordance with the Guidelines for Accommodation 
and Care of Animals (European Convention for Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes) and internal guidelines. Experimental procedures 
were approved by the ethical committee and local authorities. All animals were housed in 
ventilate cages and fed on standard diet ad libitum. 
HT1080 mouse tumor model development  
 In order to study the biodistribution of the labeled AuNPs in tumor-bearing mice, Rj:NMRI-
Foxn1
nu/nu female mice (7-8 weeks old, Janvier) were subcutaneously inoculated with 2×106 
HT1080 tumor cells in to the right flank. Prior to each inoculation, cells were diluted in sterile 
PBS:Matrigel (1:1) and Mycoplasma test (Lonza) was carried out to ensure that cells were not 
contaminated. Mice weights were measured daily. Tumors were measured and recorded 3 times 
per week with a digital caliper and volumes were calculated as V (mm3) = [(short diameter)2 x 
(long diameter)]/2. Biodistribution studies were carried out when tumor volume was 
approximately 200–300 mm3 (~15-20 days after tumor inoculation).  
Biodistribution studies 
PET studies with labeled NPs were carried out in mice (n=2 per compound) using an eXplore 
Vista-CT small animal PET-CT system (GE Healthcare). Anaesthesia was induced with 5% 
isoflurane and maintained by 1.5 to 2% of isoflurane in 100% O2. For intravenous administration 
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of the radiotracer, the tail vein was catheterized with a 24-gauge catheter and the labeled NPs 
(3.8±0.6 MBq for NPs labeled at the core; 2.7±0.3 MBq for NPs labeled at the shell, volume=150 
μL) were injected concomitantly with the start of a PET dynamic acquisition. Mice were kept 
normothermic throughout the scans using a heating blanket (Homeothermic Blanket Control 
Unit; Bruker).   
Whole body scans were acquired just after administration during 60 min. At time points 10 h, 24 
h, 72 h and 144h, 30 min whole body static acquisitions were performed. All the scans were 
recorded in the 400-700 KeV energetic window. CT acquisitions were also performed at the end 
of each PET scan, providing anatomical information for unambiguous localization of the 
radioactive signal and the attenuation map for PET image reconstruction. 
PET images were reconstructed (decay and CT-based attenuation corrected) with filtered back 
projection (FBP) using a Ramp filter with a cut off frequency of 1 Hz. Images were analysed 
using PMOD image analysis software (PMOD Technologies Ltd, Zürich, Switzerland). With that 
aim, volumes of interest (VOIs) were manually drawn in the lungs, liver, bladder, stomach, 
kidneys, spleen, tumor, heart and thyroid gland using the CT images as anatomical reference. 
VOIs were then transferred to the PET images and time activity curves (decay corrected) were 
obtained for each organ as cps/cm3. Curves were transformed into real activity (Bq/cm3) curves. 
Injected dose normalization was finally applied to data to get time activity curves as percentage 
of injected dose per cm3 of tissue.  
Ex vivo Studies 
Ion beam microscopy (IBM) studies were performed at the LIPSION nanoprobe at Leipzig 
University using a 2.25 MeV proton beam with a spot size of approximately 1 µm and supplied 
by Singletron™ particle accelerator (HVEE, Amersfoort, NL). Under vacuum of 10−6 Torr two 
ion beam microscope techniques, such as micro-proton induced X-ray emission (µPIXE) and 
micro-Rutherford backscattering (µRBS), were used simultaneously to study the spatial 
distribution of elements originated from tissue and NPs. Extracted µRBS spectra from the region 
of interest were analyzed by using SIMNRA 6.06 software (Dr. Matej Mayer, MPI of 
plasmaphysic, Garching, GE) to determine accumulated charge, area density (atoms/cm2) and 
element matrix composition (C, N, O). These parameters were used as input for µPIXE analysis 
by means of GeoPIXE 5.1 software (CSIRO Earth Science and Resource Engineering, Clayton, 
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Australia) to quantify element concentration in the tissue of NP treated mice. The detailed 
procedure is described elsewhere [29, 35]. 
Confocal Raman microspectroscopy (CRM) analyses were performed using an Alpha300 R 
microscope (WITec GmbH, Ulm, Germany) equipped with a 532 nm laser source, a 600 g 
mm−1 grating and a charge-coupled device (CCD) cooled down to −61 °C. All measurements 
were conducted using a 63x water immersion objective (W Plan-Apochromat 63x/1.0, Zeiss, 
Oberkochen, Germany). Raman spectra were collected pixel-wise in x-y plane with an integration 
time of about 70 µs. Acquired spectra were processed using the Project FOUR PLUS 4.0 
software (WITec GmbH, Ulm, Germany). 
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Chapter 4: Gold Nanoparticles as boron carriers for BNCT (II) 
4.1. Introduction 
As mentioned in the previous chapter, gold nanoparticles (AuNPs) have attracted increasing 
attention in a wide range of biomedical applications due to their unique optical, physical and 
chemical properties [1, 2]. Due to their non-toxic nature and biocompatibility, we considered 
them as potential boron carriers for boron neutron capture therapy (BNCT). This said, it is worth 
mentioning that both the core size and the surface functionalization of the NPs play a pivotal role 
when applied in biomedicine. First, it is well known that the surface-to-volume ratio of AuNPs is 
inversely proportional to their size; the smaller the particle, the higher the surface-to-volume 
ratio, and high surface-to-volume ratios offer the possibility to attach a higher amount of drug, 
targeting moieties or stabilizers on the surface.  
In our particular case, the possibility to incorporate a higher amount of boron on the surface of 
the particles should lead to higher therapeutic efficacy while using a lower net amount of AuNPs, 
with the consequent decrease both in cost and eventual off-target side effects.  
Besides the above mentioned effect, the size of the AuNPs in drug delivery also plays an 
important role in the general biodistribution. Small core-sized AuNPs, when properly stabilized, 
have prolonged plasma circulation time due to the fact that larger AuNPs are more easily cleared 
by the Mononuclear Phagocytic System (MPS), previously known as reticuloendothelial system 
(RES). Terentyuk et al. reported that 15 nm AuNPs showed prolonged blood circulation time and 
concentrations in the plasma than those of 50 and 160 nm 24 h after injection [3]. Therefore, for 
prolonging circulation of AuNPs and enable higher tumor accumulation, tuning surface 
functionality and core sizes are important factors. 
In the previous chapter, we have evaluated AuNPs (core size 18-21 nm) stabilized with 
polyethylene glycol (PEG) and functionalized with the boron-rich anion cobalt bis(dicarbollide). 
The incorporation of the positron emitter 124I enabled the pharmaciokinetic evaluation 
(biodistribution, elimination) of the NPs by means of Positron Emission Tomography (PET). 
Additionally, incorporation of the label in different positions (core and shell) confirmed stability 
in vivo of the NPs. Despite the suitability of this approach, high accumulation of the NPs in the 
liver suggested that the core size was probably too large, resultin in a very low accumulation of 
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the NPs in the tumor. Additionally, minor accumulation of radioactivity in the stomach and the 
thyroid gland confirmed progressive detachment of the radiolabel, thus suggesting that the 
radiolabeling strategy was not optimal. These results pointed to the need to slightly modify 
particle size and radiolabeling strategy in subsequent studies.  
In this chapter, as a second approach for the development of gold NP-based BNCT agents, we 
decided to prepare spherical gold NPs with smaller sizes, this is, with core sizes of ~3-4 nm 
(named GNSs) and ~9-11 nm (named GNSm). In both cases, NPs were stabilized with PEG-thiol. 
For the tracking in vivo, the positron emitter copper-64 (64Cu, half-life of 12.7 hours) was 
incorporated at the core by adapting previously reported methods [4, 5]. As the boron source, we 
used the boron cluster [4.4]- (see chapter 3) on the gold surface via Au-thiol interaction. PET 
studies were carried out in a mouse model of human gastrointestinal adenocarcinoma, generated 
by subcutaneous inoculation of MKN45 human cells in nude mice, in order to assess the in vivo 
stability of the size tuned multifunctionalized GNSs and GNSm and their capability to 
accumulate in the tumor by passive targeting (Scheme 4.1). 
 
Scheme 4.1. General scheme of the experimental part of this chapter. Radiolabeled multifunctionalized 
64Cu alloyed GNSs and GNSm nanosystems were evaluated by positron emission tomography (PET) 
imaging after intravenous administration in a mouse model of gastrointestinal adenocarcinoma.  




The specific objectives of this chapter are: 
1- To synthesize and characterize stable and biocompatible copper alloyed, size-tuned small 
(GNSs) and medium gold nanospheres (GNSm) functionalized with PEG and COSAN. 
2- To develop strategies for the radiolabeling of the nanosystems with the positron emitter 64Cu. 
3- To perform in vitro studies (cytotoxicity and cell internalization) of multifunctionalized 
GNSs and GNSm in different cell lines. 
4- To evaluate the pharmacokinetic properties of the novel multifunctionalized GNSs and 
GNSm using positron emission tomography (PET) in a human gastrointestinal 
adenocarcinoma mouse model (MKN45 human cell line) after intravenous administration. 
4.3 Results and Discussion 
4.3.1 Synthesis and Characterization of the gold nanospheres  
The synthesis of [3,3’-Co(1,2-C2B9H10)(8’-O-(CH2)5-SH-1’,2’-C2B9H11)]- ([4.4]-) was designed 
to generate thiol group-bearing COSAN derivatives for easy attachment to small sized gold 
nanospheres (GNSs, core size ~3-4 nm) and medium-sized gold nanospheres (GNSm, core size 
~9-11 nm). The boron-rich ligand was prepared as described in Chapter 3.  
For the preparation of the nanoparticles, we first tackled the synthesis of stabilized, copper-
alloyed small gold nanoparticles (Cu-GNSs@PEG) by using previously published protocols with 
slight modifications [5]. In brief, non-radioactive copper chloride dihydrate (CuCl2.2H2O) and 
HAuCl4 were dissolved in water, followed by the addition of methoxy poly(ethylene glycol) 
methyl ether thiol (mPEG-SH, 2 kDa). After 2 min, a sodium borohydride (NaBH4) solution was 
added under quick stirring for 2 min. The reaction was allowed to occur for 2 h at room 
temperature prior to centrifugation (Figure 4.1). 
Next, we prepared copper alloyed medium gold nanoparticles (Cu-GNSm@PEG), also following 
previously reported methods with slight modifications [6]. In brief, HAuCl4, copper(II) 
acetylacetonate ([Cu(acac)2]) and 1,2-hexadecanediol were mixed and oleylamine was used as a 
solvent and reducing agent in the reaction. The reaction solution was heated in a microwave to 
160°C with a programmed temperature ramp of 4°C/min. Then, the reaction mixture was held at 
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160°C for 2 h prior to cooling to room temperature. After centrifugation, the hydrophobic Cu-
GNSm NPs were dissolved in hexane to form a homogeneous reddish solution. Subsequently, the 
hydrophobic Cu-GNSm NPs were modified with a thiol-terminated poly(ethylene glycol) 
(methoxy-PEG-SH, 2 kDa). With that aim, mPEG2k-SH was dissolved in water and added 
dropwise to the Cu-GNSm NPs in a tetrahydrofuran (THF) solution and stirred for 24 h at room 
temperature prior to centrifugation to get hydrophilic Cu-GNSm@PEG (Figure 4.2). 
 
Figure 4.1. Schematic representation of the preparation of Cu-GNSs@PEG. 
 
Figure 4.2. Schematic representation of the preparation of Cu-GNSm@PEG 
In the next step, PEG-stabilized GNSs and GNSm NPs were functionalized with COSAN-thiol 
([4.4]-). With that aim, compound [4.4]- was dissolved in ethanol, and this solution was added to 
the Cu-PEG-GNSs and Cu-PEG-GNSm solution drop-wise. The resulting solution was stirred for 
2 h at RT and purified by centrifugation to get Cu-GNSs-PEG@[4.4]- (Figure 4.3) and Cu-
GNSm-PEG@[4.4]- (Figure 4.4).  
THF, 24 h, rt 




Figure 4.3. Schematic representation of the preparation of Cu-GNSs-PEG@[4.4]- 
 
Figure 4.4. Schematic representation of the preparation of Cu-GNSm-PEG@[4.4]- 
One of the important parameters to take into consideration when preparing new BNCT drug 
candidates is the boron-load capacity. In order to check the loading capacity of [4.4]- on Cu-PEG-
GNSs and Cu-PEG-GNSm, optimization studies were performed by adding different amounts of 
[4.4]
- (GNSs/GNSm to [4.4]- molar ratios: 1, 2 and 0.66) to the nanosystems. The absorbance and 
loading capacity of both nanosystems after purification was analyzed by UV-vis absorption 
spectroscopy (UV-Vis). The surface functionalized nanosystems showed a longitudinal surface 
plasmon resonance (LSPR) band at 521 nm for Cu-GNSs-PEG@[4.4]-, while for Cu-GNSm-
PEG@[4.4]- the LSPR band observed at 529 nm. Additionally, another absorption band appeared 
at ca. 310 nm, close to the maximum absorption of COSAN (314 nm), confirming successful 
attachment of the boron cluster on the surface of the Cu-GNSs-PEG@[4.4]- and Cu-GNSm-
PEG@[4.4]- nanosystems (Figure 4.5). In all experimental scenarios, NPs showed good stability, 
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and hence we decided to move forward using the NPs prepared with a GNSs/GNSm to [4.4]- 
molar ratio of 0.66, as this was expected to result in the higher concentration of boron on the 
NPs.  
 
Figure 4.5. UV-vis-NIR spectra of Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]- with different 
molar ratios of GNSs or GNSm to [4.4]-.  
Transmission electron microscopy (TEM) images showed that Cu-GNSs-PEG@[4.4]- had 
uniform distribution with a core diameter of 3.5 ± 1.8 nm (Figure 4.6a) and zeta potential 
measurements showed a negative ξ-potential of −36.0±2 mV (Figure 4.6b). 
 
 
Figure 4.6. Transmission electron micrograph (TEM) (a) and Zeta potential distribution for Cu-GNSs-
PEG@[4.4]- (-36±2 mV). 
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Cu-GNSm-PEG@[4.4]- showed the similar uniform distribution with a core diameter of 9.5 ± 2.5 
nm (Figure 4.7a), and a negative ξ-potential of −19.0±2 mV (Figure 4.7b) at neutral pH. The 
negative zeta potential values confirm the incorporation of the anionic COSAN complex on the 
surface of both nanosystems. 
 
Figure 4.7. Transmission electron micrographs (TEM) (a) and Zeta potential distribution for Cu-GNSm-
PEG@[4.4]- (-19±2 mV) (b). 
As additional structural evidence, the presence of COSAN on the surface of gold nanoparticles 
was confirmed by X-ray photoelectron spectroscopy (XPS). XPS analysis of Cu-GNSs-
PEG@[4.4]- and Cu-GNSm-PEG@[4.4]- showed boron and cobalt peaks at 780.2 eV and 192.8 
eV respectively (Figure 4.8) [7].  
 
Figure 4.8. XPS spectra of Cu-GNSs-PEG@[4.4]-  (a) and Cu-GNSm-PEG@[4.4]- (b). 
The relative quantification of carbon, oxygen, boron and cobalt present in the samples was 
carried out (Table 4.1). The quantification data showed that Cu-GNSs-PEG@[4.4]- have a higher 
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amount of boron when compared with Cu-GNSm-PEG@[4.4]-. These results confirmed the 
presence of both boron and cobalt on the surface of both nanosystems. 
Table 4.1. Elemental composition of different elements present in the Cu-GNSs-PEG@[4.4]- and Cu-
GNSm-PEG@[4.4]- nanosystems measured by XPS analysis. 
 C(at.%) O(at.%)  Co(at.%) B(at.%) 
Cu-GNSs-PEG@[4.4]
-
 46.5 26.1 0.4 13.4 
Cu-GNSm-PEG@[4.4]
-
 48.4 25.4 0.3 8.9 
 
In order to determine the loading capacity of the both nanosystems, ICP-MS analysis were 
performed to measure the gold and boron content in the final Cu-GNSs-PEG@[4.4]- and Cu-
GNSm-PEG@[4.4]-, (GNSs and GNSm to [4.4]- molar ratios 0.66). The amount of [4.4]- was in 
Cu-GNSs-PEG@[4.4]- estimated to be 472 µg per mg of gold, which results in ca. 210 µg of 
boron/mg of gold. The amount of [4.4]- in Cu-GNSm-PEG@[4.4]- was calculated to be 348 µg 
per mg of gold, which results in ca. 155 µg of boron/mg of gold. These results confirm that both 
Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]- have a significant boron load and ready for 
for eventual in vitro and in vivo studies. 
4.3.2. In vitro studies 
Cytotoxicity studies 
To determine cytotoxicity of the Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]-, human 
dermal fibroblasts (HDFa), MKN-45 gastric adenocarcinoma cells and 3T3 cells (cell line 
originally established from primary mouse embryonic fibroblast cells) were treated with 20, 40, 
and 60 μM (gold concentration) of the nanosystems for up to 72 hours prior to analysis using the 
MTT assay. Both nanosystems did not induce cell death at up to 60 μM (gold concentration) in 
any of the tested cell lines (Figure 4.9), indicating negligible cytotoxicity. 




Figure 4.9. Cell viability in the presence of Cu-GNSs-PEG@[4.4]- (a) and Cu-GNSm-PEG@[4.4]- (b), 
for 24, 48 and 72 hours: a) human (HDFa) dermal fibroblasts; b) MKN-45 gastric cell line and c) 3T3 
healthy mouse cell line. In all cases, cells were incubated with increasing concentrations of GNSs and 
GNSm and cell viability was determined by the MTT assay. Data are shown as the mean ± standard 
deviation of three independent experiments. 
Cell internalization studies 
The cellular uptake of multifunctionalized GNSs and GNSm was evaluated in MKN-45 cells 
using fluorescence microscopy. For that purpose, the first step was to incorporate a fluorescent 
moiety in the NPs. With that aim, Cu-GNSs-PEG@[4.4]- was reacted with PEG-amine-thiol 
(5 kDa) at room temperature for 2 h and centrifuged at 14000 rpm for 10 min and washed two 
times with water. Then, Cyanine 3 N-hydroxysuccinimide ester (Cy3-NHS) dissolved in DMSO 
was added to the amino-functionalized Cu-GNSs-PEG@[4.4]- (pH 7.4-8.0) and stirred for 2 h at 
room temperature. The resulting particles were centrifuged at 14000 rpm for 10 min and washed 
two times with water. A parallel synthesis strategy was applied to prepare fluorophore-labeled 
Cu-GNSm-PEG@[4.4]- NPs.  




Figure 4.10. Live cell fluorescence microscopy of multifunctionalized GNSs and GNSm after 2 h 
incubation with MKN45 cells. In green: Cu-GNSs-mPEG@[4.4]- (a) and Cu-GNSm-mPEG@[4.4]- (b), 
fluorophore-labeled with NHS-Cy3, in red: Lysosomes, stained with LysoTracker deep red, in blue: 
nucleus, stained with Hoechst33342. Merged signals of fluorophore-labeled (a) and (b), colocalizing with 
lysosomes appear in yellow. 
Both fluorophore-labeled NPs (Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]-) were 
incubated with MKN45 cells for 2 h. To enable visualization of co-localization between the 
fluorophore-labeled Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]- with the lysosomes, the 
lysosomes were stained with Lysotracker-deep-red. Images were taken using a live cell Axio 
Observer (Zeiss) fluorescence microscope and analyzed by the ZEN-ZEISS software, showing a 
clear co-localization of Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]- and the lysosomes 
(Figure 4.10). Our results confirm that both nanosystems can efficiently internalize in MKN45 
cells in 2 hours. 
4.3.3. Radiolabeling of nanoparticles 
Radiolabeled GNSs and GNSm with the positron emitter 64Cu were synthesized by using 
previously published protocols with minor modifications [5, 6]. In brief, 64Cu-GNSs-PEG@[4.4]- 
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labeled NPs were synthesized as Cu-GNSs-PEG@[4.4]- NPs, but radioactive [64Cu]CuCl2 was 
added instead of CuCl2.2H2O (Figure 4.11). In order to remove all the 64Cu absorbed on (or 
loosely bound to) the NPs, the synthesized 64Cu-GNSs-PEG NPs were challenged with 
ethylenediaminetetraacetic acid (EDTA, 10 mM in neutral 50 mM phosphate buffer, 5 µL), and 
then purified using a centrifuge filter (Amicon, MWCO 10 kDa). The radiochemical purity was 
above 95%, as determined by instant radio-thin layer chromatography (radioTLC) (Figure 4.12). 
In the second step [4.4]- was attached as described in non-radioactive Cu-GNSs-PEG@[4.4]- 
preparation (Figure 4.12). After purification, the radiochemical yield of 64Cu-GNSs-PEG@[4.4]- 
was 15% and purity was above 98% (Figure 4.13). 
 
Figure 4.11. Schematic representation of the preparation of 64Cu-GNSs-PEG@[4.4]-. 
 
Figure 4.12. Radiochemical purity of 64Cu-GNSs-PEG analyzed by radioTLC. 




Figure 4.13. Radiochemical purity of 64Cu-GNSs-PEG@[4.4]- analyzed by radioTLC. 
64Cu-radiolabeled GNSm NPs were synthesized following the same protocol used for the 
preparation of non-radioactive Cu-GNSm-PEG@[4.4]-, although 64CuCl2 was added to the 
reaction mixture. In brief, 64Cu labeled hydrophobic GNSm NPs were prepared by addition of 
radioactive [64Cu]CuCl2 to the HAuCl4, copper(II) acetylacetonate ([Cu(acac)2]) and 1,2-
hexadecanediol solution. To this mixture oleylamine was added. The reaction solution was heated 
in a microwave to 160°C with a programmed increase of 4°C/min. The reaction was then held at 
160°C for 2 h, and was then cooled to room temperature. After centrifugation, the hydrophobic 
64Cu-GNSm NPs were obtained and dissolved in hexane to form a homogeneous reddish 
solution. The synthesized 64Cu-GNSm NPs were further functionalized with PEG and COSAN-
SH by following the same procedure as nonradioactive Cu-GNSm-PEG@[4.4]- (Figure 4.14). 
The radiochemical yield of 64Cu-GNSm-PEG@[4.4]- was 18% (non-decay corrected) and 
radiochemical purity was determined by radioTLC as above 98% (Figure 4.15). 




Figure 4.14. Schematic representation of the preparation of 64Cu-GNSm-PEG@[4.4]- 
 
Figure 4.15. Radiochemical purity of 64Cu-GNSm-PEG@[4.4]- analyzed by radioTLC. 
4.3.4. Radiochemical stability 
Radiochemical stability of both 64Cu-GNSs-PEG@[4.4]- and 64Cu-GNSm-PEG@[4.4]- 
nanosystems was tested in phosphate buffered saline (PBS), PBS with a challenging agent 
(ethylenediaminetetraacetic acid; EDTA, 2.5 mM), saline solution (0.9% NaCl), saline solution 
with EDTA and mouse serum. The stability was checked by incubating the nanoparticles at 37°C 
THF, 24 h, rt 
Chapter 4 – GPSs as boron carriers for BNCT (II)  
72 
 
for up to 48 h. Both nanosystems showed excellent stability in all the media without any 
significant detachment of 64Cu from the gold core (Figure 4.16). 
 
Figure 4.16. Radiochemical stability of 64Cu-GNSs-mPEG@[4.4]- (a) and 64Cu-GNSm-mPEG@[4.4]- (b) 
at different incubation times (1, 6, 24 and 48 h) in physiological saline (0.9% NaCl), physiological saline 
solution containing EDTA (0.9% NaCl + 2.5 mM EDTA), phosphate buffered saline (PBS), phosphate 
buffered saline containing EDTA (PBS + 2.5 mM EDTA), and mouse serum. 
4.3.5 In vivo biodistribution studies 
The in vivo distribution of the labeled particles, 64Cu-GNSs-PEG@[4.4]- and 64Cu-GNSm-
PEG@[4.4]-, was carried out using PET in combination with Computerized Tomography (CT). 
To evaluate the capacity of the nanosystems to accumulate in tumor, a human gastrointestinal 
adenocarcinoma mouse model (generated by subcutaneous inoculation of MKN45 cells) was 
used. The general biodistribution of both radiolabeled nanosystems and the accumulation in the 
tumor after intravenous administration were determined by acquiring static PET images at 
different time points (1, 6, 24 and 48 hours; see Figures 4.17 and 4.20 for representative images). 





Figure 4.17. Representative PET images (coronal and axial views) obtained at 1, 6, 24, and 48 hours after 
administration of 64Cu-GNSs-PEG@[4.4]- in mice bearing MKN-45 tumor. Maximum intensity projection 
(MIP) PET images were co-registered with representative CT coronal slices. The position of the tumor is 
indicated with white arrows. 
Volumes of interest (VOIs) were drawn in major organs and tumor tissue based on reconstructed 
CT images, and used to quantify PET images. The amount of radioactivity in each region was 
determined as percentage of injected dose per cubic centimeter of tissue (%ID/cm3) (Figure 4.18). 
In the case of 64Cu-GNSs-PEG@[4.4]- NPs, at t = 1 hour time point, high amount of radioactivity 
was observed in the heart (13.29±3.0 %ID/cm3), indicating the presence of a significant amount 
of labeled GNSs in the blood pool. This value progressively decayed with time, to reach a value 
of 2.27±1.0 %ID/cm3 at t = 48 hours. 




Figure 4.18. Accumulation of 64Cu-GNSs-PEG@[4.4]- in different organs at different time points after 
intravenous administration, analyzed by PET imaging (values are expressed as mean ± standard error 
mean, n = 3). 
At t = 1 hour, high accumulation of GNSs was observed in liver (31.42±3.0 %ID/cm3), while 
accumulation in lungs (4.33±2.3 %ID/cm3) and spleen (4.82±1.6 %ID/cm3) was lower. In the 
liver and lungs, a progressive decrease of radioactivity concentration was observed over time, 
reaching values of 10.37±2.5 %ID/cm3 and 1.96±0.7 %ID/cm3, respectively, at t = 48 hours 
(Figure 4.18). These results suggest that GNSs NPs were moderately sequestrated by organs of 
the mononuclear phagocyte system (MPS). Lower accumulation in kidneys (i.e. 4.15±0.9 
%ID/cm3), and no significant elimination via urine were observed. A progressive accumulation of 
GNSs in spleen was observed over time. Noteworthy, the concentration of radioactivity in the 
tumor progressively increased with time (Figure 4.19) to reach the maximum value at t = 24 
hours (5.3±1.3 %ID/cm3) and slowly decreased afterwards (3.92±1.7 %ID/cm3 at t = 48 hours).  
 
Figure 4.19. Accumulation of 64Cu-GNSs-PEG@[4.4]- in tumor at different time points after 
administration (1, 6, 24 and 48 h). 
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In the case of 64Cu-GNSm-PEG@[4.4]- NPs, high accumulation was observed in the liver at all 
times) and low accumulation was observed in all other major organs (Figures 4.20 and 4.21). The 
concentration of radioactivity in the tumor increased to 1.3±1.1 %ID/cm3 at t = 48 hours (Figure 
4.22).  
 
Figure 4.20. Representative PET images (coronal and axial views) obtained at 1, 6, 24, and 48 hours after 
administration of 64Cu-GNSm-PEG@[4.4]- in mice bearing MKN-45 tumor. Maximum intensity 
projection (MIP) PET images were co-registered with representative CT coronal slices. The position of the 
tumor is indicated with white arrows. 
 
Figure 4.21. Accumulation of 64Cu-GNSm-PEG@[4.4]- in different organs at different time points after 
intravenous administration, analyzed by PET imaging (values are expressed as mean ± standard error 
mean, n = 3). 





Figure 4.22. Accumulation of 64Cu-GNSm-PEG@[4.4]- in the tumor at different time points (1, 6, 24 and 
48 h) after intravenous administration. 
4.3.6 Ex vivo studies 
Ex vivo gamma-counting experiments were conducted for both 64Cu-GNSs-PEG@[4.4]- and 
64Cu-GNSm-PEG@[4.4]- nanosystems immediately after finalizing the last imaging session at 48 
h time point. Organs of interest were harvested and the amount of radioactivity in each organ was 
measured in an automated gamma-counter (Wallach Wizard, PerkinElmer, Waltham, MA, USA) 
(Figure 4.23). The ex vivo results of both nanosystems were in good agreement with in vivo PET 
quantification. 
 
Figure 4.23. Accumulation of 64Cu-GNSs-PEG@[4.4]- and 64Cu-GNSm-PEG@[4.4]- in different organs 
after ex vivo analysis at 48 h time point, analyzed by gamma counter (values are expressed as mean ± 
standard error mean, n = 3 per NP type). 
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As mentioned previously, one of the problems to follow the biodistribution of the NPs may arise 
from eventual detachment of the radiolabel. In order to prove that the distribution data obtained 
by in vivo PET and ex vivo gamma counting actually reflect the distribution of the particles, we 
carried out ICP-MS analysis of selected organs. The boron and gold concentration determined by 
ICP-MS confirmed the stability of the NPs and correlated well with data obtained from studies 
conducted with radioactivity measurements, thus confirming the suitability of our approach and 
the capacity of the nanoparticles to reach the tumor (Figure 4.24).  
 
Figure 4.24. Amount of gold and boron in, liver, spleen and the tumor at 48 hours after intravenous 
administration of 64Cu-GNSs-PEG@[4.4]- and 64Cu-GNSm-PEG@[4.4]-, as determined by ICP-MS and 
ex vivo gamma counting.  
With the results obtained, we made some estimation of the potential therapeutic efficacy of the 
small gold NPs, which showed enhanced accumulation in the tumor. Considering that: (i) the 
injected dose to the animal was 200 µg of 64Cu-GNSs-PEG@[4.4]- (amount of gold); (ii) GNSs 
contain 210 µg boron per mg of gold; and (iii) the concentration of GNSs in the tumor at t = 24 
hours after administration is 5.3±1.3 %ID/cm3, the average concentration of boron in the tumor at 
t = 24 hours is 2.22 µg/cm3. In the case of 64Cu-GNSm-PEG@[4.4]-, the injected dose to the 
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animal was 180 µg (amount of gold); (ii) GNSm contain 155 µg boron per mg of gold; and (iii) 
the concentration of GNSs in the tumor at t = 48 hours after administration is 1.3±0.3 %ID/cm3, 
the average concentration of boron in the tumor at t = 48 hours is 0.3 µg/cm3. These values, 
despite they could be improved by administering a higher dose to the animals, are below the 
threshold perceived as sufficient to guarantee therapeutic efficacy. Hence, we next tackled the 
design of nanosystems suitable for dual therapeutic approaches (see chapter 5). 
4.4. Conclusions  
The synthesis of medium- (ca. 10 nm) and small- (ca. 3 nm) sized gold NPs, containing copper at 
the core and functionalized with COSAN and thiolated polyethylene glycol can be achieved by 
using adapted methods. The presence of the copper at the core enables the radiolabeling using the 
positron emitter 64Cu. The labeled particles showed good stability in vivo, low toxicity in vitro  
and fast internalization in MKN45 cells. PET images following the intravenous administration of 
small gold nanospheres showed significant accumulation in the tumor at 24–48 hours after 
administration, whereas medium size particles showed moderate tumor uptake and major 
accumulation in the liver. In both cases, the accumulation of boron in the tumor is insufficient to 
tackle therapy experiments. These results suggest that nanosystems enabling dual therapeutic 
approaches may be required.  
4.5. Experimental section 
4.5.1. Reagents 
Cesium cobalt(III) bis(dicarbollide) (COSAN) (Katchem Ltd., Prague, Czech Republic), 
tetrahydropyran (sigma Aldrich), gold(III) chloride trihydrate (HAuCl4·3H2O, Aldrich), copper 
(II) acetylacetonate (Cu(acac)2), oleylamine, 1,2-hexadecanediol (TCI, Spain), hydrochloric acid 
(HCl, 37%, TraceSELECT®), nitric acid (HNO3, 70%, ≥99.999% trace metals basis), sodium 
borohydride, copper chloride (CuCl2.2H2O), poly (ethylene glycol) methyl ether thiol (MW 2000, 
Sigma-Aldrich) and cyanine 3 N-Hydroxysuccinimide ester (Cy3-NHS) from BroadPharm®, 
were used as purchased. All other reagents and anhydrous solvents, stored over 4 Å molecular 
sieves, were purchased from Aldrich Chemical Co. (Madrid, Spain) and used without further 
purification. HPLC grade solvents were purchased from Scharlab (Sentmenat, Barcelona, Spain). 
64Cu2+ dissolved in 0.1M HCl was produced at CIC biomaGUNE Radiochemistry facility by 
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proton irradiation of 64Ni via the 64Ni(p,n)64Cu nuclear reaction using standard protocols [Kume, 
2012 #49]. 
In chemical syntheses, experiments were carried out, except when noted, under a dry, oxygen-
free dinitrogen atmosphere. The microwave synthesis of GNSm NPs was performed on a CEM 
Discover-SP. Column chromatography was performed using silica gel 60 (Scharlab, Spain). 
Analytical thin layer chromatography (TLC) measurements were conducted with silica gel 60 
F254 plates (Macherey-Nagel); and the spots were visualized under UV lamp.  
4.5.2. Instrumentation: 
The 1H-NMR (500 MHz), 13C-NMR (126 MHz) and 11B-NMR (160 MHz) spectra were recorded 
on a 500-MHz Avance III Bruker spectrometer. All NMR spectra were performed in deuterated 
solvents at 22 °C. The 11B-NMR shifts were referenced to external BF3·OEt2, while the 1H and 
13C-NMR shifts were referenced to SiMe4. Chemical shifts are reported in units of parts per 
million (ppm) downfield from the reference peak and all coupling constants are reported in Hertz 
(Hz).  
UPLC/ESI-MS analyses were performed using an AQUITY UPLC separation module coupled to 
LCT TOF Premier XE mass spectrometer (Waters, Manchester, UK). An Acquity BEH C18 
column (1.7 µm, 5 mm, 2.1 mm) was used as stationary phase. The elution buffers were A (water 
and 0.1% formic acid) and B (Methanol and 0.1% formic acid). The column was eluted with 
gradient: t=0 min, 95% A, 5% B; t=0.5 min, 95% A, 5% B; t=5.5 min, 25% A, 75% B; t=16 min, 
1% A, 99% B; t=20min, 1% A, 99% B. Total run was 20 min, injection volume was 5 µL and 
flow rate 300 µL/min. The detection was carried out in both, negative and positive ion mode, 
monitoring the most abundant isotope peaks from the mass spectra (M-H+) or (M+H+). 
Ultraviolet-Visible-Near infrared (UV-Vis-NIR) spectra were measured in an Agilent 8453 UV-
Vis-NIR diode-array spectrophotometer.  
ξ-potential measurements were performed at neutral pH using a Malvern Zetasizer Nano ZS 
system (Malvern Instruments, Malvern, UK).  
Transmission electron microscopy (TEM) was performed using a JEOL JEM-1400 plus 
microscope (Jeol, Tokyo, Japan) working at 120 kV. The carbon film of copper grids (CF400-
Cu) was treated under air plasma in a glow discharge system (Emitech K100X, 40mA during 2 
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min) just before sample preparation. For TEM examinations, a single drop (1 μL) of the NPs 
solution was placed onto a copper grid coated with a carbon film (Electron Microscopy 
Sciences).  
X-ray photoelectron spectroscopy (XPS) experiments were performed in a SPECS Sage HR 100 
spectrometer with a non-monochromatic X ray source (Aluminium Kα line of 1486.6 eV energy 
and 252 W), placed perpendicular to the analyser axis and calibrated using the 3d5/2 line of Ag 
with a full width at half maximum (FWHM) of 1.1 eV. The selected resolution for the spectra 
was 15 eV of Pass Energy and 0.15 eV/step. All measurements were made in an ultra-high 
vacuum (UHV) chamber at a pressure around 6×10-8 mbar. An electron flood gun was used for 
charge neutralisation. Gaussian Lorentzian functions were used for fittings (after a Shirley 
background correction) where the FWHM of all the peaks were constrained while the peak 
positions and areas were set free. Main C1s peak was used for charge reference and set at 284.8 
eV. 
Gamma counting experiments were carried out using a Wallach Wizard, PerkinElmer (Waltham, 
MA, USA) gamma counter. 
ICP-MS measurements were performed on a Thermo iCAP Q ICP-MS (Thermo Fisher Scientific 
GmbH, Bremen, Germany). An ASX-560 autosampler was coupled to the ICP-MS (CETAC 
Tech, Omaha, NE, USA).  
Cell observer microscopy experiments were carried out using a Zeiss Axio Observer 
Fluorescence microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and 
analyzed by ZEN2012-ZEISS. 
Confocal cell microscopy experiments were carried out using a Zeiss 880 Confocal Fluorescence 
microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and analyzed by 
ZEN2012-ZEISS. 
Radio-thin layer chromatography (radio-TLC) was performed using iTLC-SG chromatography 
paper (Agilent Technologies, CA, USA) and 20 mM citric acid + 60 mM EDTA/acetonitrile 
solution (9/1 v/v) as the stationary and mobile phases, respectively. TLC plates were analyzed 
using a TLC-reader (MiniGITA, Raytest). 
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4.5.3 Chemistry and radiochemistry 
Synthesis of non-radioactive Cu-GNSs@PEG 
In a typical reaction, water (1.0 mL), HAuCl4 (10 mM, 94 µL), and CuCl2.2H2O (10 mM, 94 µL) 
were mixed in a glass vial, followed by the dropwise addition of mPEG-thiol (MW = 2000 Da, 7 
mM, 200 µL). To this mixture was added sodium borohydride (20 mM, 200 µL) under quick 
stirring for 2 min at room temperature and then kept for 2 hours. The Cu-GNSs-PEG NPs were 
purified using a centrifuge filter (Amicon, 10 kDa MWCO) and washed with MilliQ water (MQ) 
three times to remove unbound mPEG. 
Synthesis of Cu-GNSs-PEG@[4.4]- 
To the obtained Cu-GNSs-PEG NPs (210 µg of gold) was added COSAN-SH ([4.4]-) (10 mM, 
200 µL) under quick stirring at room temperature and then continued for 2 hours. The Cu-GNSs-
PEG@[4.4]- were purified using a centrifuge filter (Amicon, 10 kDa MWCO) and washed with 
MilliQ water three times to remove unbound [4.4]-.  
Synthesis of 64Cu-GNSs-PEG@[4.4]- 
Synthesis of 64Cu-GNSs-PEG@[4.4]- was carried out following the same procedure as that used 
for preparing non-radioactive Cu-GNSs-PEG@[4.4]-. Instead of adding CuCl2.2H2O in the first 
step, radioactive 64CuCl2 (222 MBq) was added. The synthesized 64Cu-GNSs-PEG NPs were 
treated with ethylenediaminetetraacetic acid (EDTA, 10 mM in neutral 50 mM phosphate buffer, 
5 µL) and then purified using a centrifuge filter (Amicon, 10 K). The radiochemical purity was 
determined by instant radio-thin layer chromatography (RadioTLC). In the second step COSAN-
SH was attached as described above.  
Synthesis of non-radioactive Cu-GNSm NPs 
Cu-GNSm NPs nanoparticles were synthesized by reducing Cu(acac)2 and HAuCl4 in 
oleylamine. Typically, HAuCl4.3H2O (0.08 mmol, 0.0256 g), Cu(acac)2 (0.026 mmol, 0.007 g) 
and 1,2-hexadecanediol (0.4 mmol, 0.010 g ) were mixed and dissolved in oleylamine (2 mL) 
under N2 atmosphere. Then the resulting solution was heated to 160°C in microwave (CEM 
Discover-SP) at the heating rate of 4°C/min. After the reaction temperature was kept at 160°C for 
2 hours, the solution was cooled to room temperature. The solution was centrifuged and washed 
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twice with ethanol (2 mL) to remove impurities. The Cu-GNSm NPs nanoparticles were 
dispersed in hexane. 
Synthesis of non-radioactive Cu-GNSm-PEG NPs 
The mPEG-thiol (MW = 2000 Da, 7 mM) was dissolved in THF (0.5 mL), added to the Cu-
GNSm NPs and stirred for 24 h at room temperature. The mixture was then centrifuged at 10.000 
rpm for 8 min to obtain PEGylated GNSm NPs. The Cu-GNSm-PEG was dissolved in MilliQ 
water (3 mL) and centrifuged at 10.000 rpm for 10 min with centrifuge filter (Amicon, 30K, 3 
mL). The procedure was repeated three times to remove unbound mPEG. 
Synthesis of Cu-GNSm-PEG@[4.4]-  
The COSAN-SH ([4.4]-) (0.5 mg) in EtOH (100 µL) was added to the Cu-GNSm-PEG 
nanoparticles purified by MilliQ water washing (0.3 mg/mL). Afterwards, the solution was 
stirred at room temperature for 2 h. The mixture was then centrifuged at 10.000 rpm for 8 min 
using centrifuge filter (Amicon, 30K, 4 mL). The procedure was repeated three times to remove 
unbound [4.4]-. 
Synthesis of 64Cu-GNSm-PEG@[4.4]- 
The synthesis of 64Cu-GNSs-PEG@[4.4]- was carried out following the same procedure as the 
preparation of non-radioactive Cu-GNSs-PEG@[4.4]- nanoparticles except for the extra addition 
of 64CuCl2 (370 MBq, 10μL) to the mixture. Then the solution was heated in microwave to 160°C 
using a heating ramp of 4°C/min. After 2 hours, the solution was cooled to room temperature. The 
synthesized 64Cu-GNSs-PEG@[4.4]- was purified and functionalized with mPEG-SH and [4.4]- 
by following the same procedure as nonradioactive Cu-GNSs-PEG@[4.4]-. 
Synthesis of fluorophore labeled GNSs and GNSm 
The synthesis was performed as described previously, but a mixture of 10 % PEG-amine and 90 
% PEG-methoxy was used to enable subsequent attachment of the fluorophore Cyanine3-NHS. 
To attach the fluorophore, 200 µL of functionalized AuNP (1 mg/mL for GNSs or GNSm 
medium in MQ water) were adjusted to pH 8.6-8.9 and 5 µL Cy3-NHS (1 mg/mL in DMSO) 
were added. After 1 h incubation at room temperature, the resulting NPs were centrifuged at 
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8.000×g for 20 min and resuspended in MilliQ water. The labeling was confirmed by UV-VIS 
spectrophotometry. 
4.5.4. In vitro studies 
Cytotoxicity studies 
To determine cell viability, MKN45 human cancer cells, 3T3 healthy mouse cells and human 
dermal healthy fibroblasts (HDFa) cells were incubated with the multifunctionalized GNSs and 
GNSm over 24, 48 and 72 hours. Cells were seeded (3×104 cells/well, 100 μL/well, 96-well 
plate), allowed to adhere overnight in complete media (10% Fetal Bovine Serum (FBS) and 1% 
Penicillin/Streptomycin in RPMI 1640 medium for MKN45 cells, DMEM medium for HDFa 
cells and 3T3 healthy cells) and maintained in a humid atmosphere at 37°C and 5% CO2. Then, 
media was removed and cells were left untreated (blank) or incubated with the GNSs and GNSm-
containing formulations, diluted accordingly in media. The experiments were performed in 
triplicates. After the desired time, cell supernatant was removed and 100 μL/well of MTT reagent 
(Roche), diluted in the corresponding media to the final concentration of 0.25 mg/mL, was added. 
After 1 hour incubation at 37°C and 5% CO2, the excess reagent was removed and formazan 
crystals were solubilized by adding 200 μL of DMSO per well. The optical density of each well 
was measured in a TECAN Genios Pro 96/384 microplate reader at 550 nm. Data was 
represented as the percentage of cell survival compared to control wells. 
Cell internalization studies 
MKN45 cells were seeded in an ‘Ibidi’ µ-slide 8-well-plate (20.000 cells/well in 0.3 mL) and 
incubated overnight to adhere (37 °C, 5% CO2, humid atmosphere). The media was removed and 
0.1 mL Hoechst 33342 (1 µg/mL in media) added to stain the nucleus. After 10 min incubation 
(37 °C, 5% CO2, humid atmosphere) 0.1 mL LysoTracker deep red (1 µg/mL in media) was 
added to stain the lysosomes. After 20 min incubation (37 °C, 5% CO2, humid atmosphere) 
media was removed and 0.3 mL of Cy3-labeled GNSs or GNSm (20 µg/mL in medium) were 
added. After 2 h incubation (37 °C, 5% CO2, humid atmosphere) the media was removed and 
replaced with fresh media. The images were taken with a Cell Axio Observer Fluorescence 
Microscope. Controls of single staining for each fluorophore were included. Images were 
analyzed by ZEN-ZEISS software. 
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4.5.5. In vivo experiments 
Animals 
The animals were maintained and handled in accordance with the Guidelines for Accommodation 
and Care of Animals (European Convention for Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes) and internal guidelines. Experimental procedures 
were approved by the ethical committee and local authorities. All animals were housed in 
ventilate cages and fed on standard diet ad libitum. 
MKN45 mouse tumor model development 
 In order to study the biodistribution of the GNSs and GNSm in tumor-bearing mice, Rj:NMRI-
Foxn1
nu/nu female mice (7-8 weeks old, Janvier) were subcutaneously inoculated with 2×106 
MKN45 tumor cells in the right back. Prior to each inoculation, cells were diluted in sterile PBS: 
Matrigel (1:1) and Mycoplasma test (Lonza) was carried out to ensure that cells were not 
contaminated. Tumors were measured every 2–3 days with a digital caliper and volumes were 
calculated as V (mm3) = [(short diameter)2 x (long diameter)]/2. Biodistribution studies were 
carried out when tumor volume was approximately 200–300 mm3 (~15 days after tumor 
inoculation).  
Biodistribution studies 
PET studies with 64Cu-labeled multifunctionalized GNSs and GNSm were carried out in MKN45 
tumor-bearing mice (n=3 per NP type) using an eXplore Vista-CT small animal PET-CT system 
(GER healthcare). Anesthesia was induced with 3% isoflurane and maintained by 1.5 to 2% of 
isoflurane in 100% O2. For intravenous administration of the radiotracer, the tail vein was 
catheterized with a 24-gauge catheter and the labeled NPs (ca. 3–10 MBq) were injected. PET 
images were analyzed using PMOD image analysis software (PMOD Technologies Ltd, Zürich, 
Switzerland). Volumes of interest (VOIs) were manually drawn in lungs, liver, heart, kidneys, 
spleen, brain, stomach, tumor and bladder using CT images as anatomical reference. VOIs were 
then transferred to the PET images and time activity curves (decay corrected) were obtained for 
each organ as cps/cm3. Curves were transformed into real activity (Bq/cm3) curves. Injected dose 
normalization was finally applied to data to get time activity curves as percentage of injected 
dose per cm3 of tissue (%ID/cm3).  
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In vivo imaging studies using PET in combination with Computerized Tomography (CT) were 
carried out in a human gastrointestinal adenocarcinoma mouse model (MKN45 human cell line) 
with Cu-GNSs-PEG@[4.4]- and Cu-GNSm-PEG@[4.4]-. Static images were acquired (total 
acquisition time of 30 min) after 1h administration of Cu-GNSs-PEG@[4.4]- and Cu-GNSm-
PEG@[4.4]- and further static acquisitions were recorded at t = 6 h, 24 h and 48 h post-
administration.  
4.5.6. Ex vivo studies 
Mice submitted to imaging sessions were sacrificed at 48 hours post injection, after the last 
imaging session. Organs of interest were collected and weighed, and the radioactivity was 
measured in a well gamma-counter (Wallach Wizard, PerkinElmer, Waltham, MA, USA). The 
uptake of 64Cu in the different organs was calculated as a percentage of the injected dose per 
gram of tissue (%ID/g) according to the prepared standards. The weighed organs (liver, spleen 
and tumor) were then immersed in digest solution (HNO3/HCl = 1:1) with a volume of 5 mL. The 
dispersions were heated to boiling until organs were completely dissolved. 1 mL of H2O2 was 
then added into the solution, and heating continued until the solution became clear and 
transparent. The solution was then cooled to room temperature, diluted by 2% HNO3 to 15 mL, 
and subsequently analyzed by ICP-MS to determine the concentration of Au and B in each 
sample. 
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Chapter 5: Gold Nanorods as boron carriers for BNCT 
5.1. Introduction 
In the last two chapters, the application of spherical gold NPs as boron-carriers with potential 
application in Boron Neutron Capture Therapy (BNCT) has been explored. The results obtained 
suggest that the amount of boron accumulated in the tumor models investigated is insufficient to 
tackle in vivo therapeutic experiments. In view of the results, we decided to explore nanosystems 
enabling the combination of two therapeutic approaches, and the natural selection is gold 
nanorods (GNRs). Indeed, the shape of nanoparticles has been recognized as a key factor 
influencing biodistribution, blood circulation time and cellular uptake in cancer drug delivery [1, 
2]. This is also the case for gold nanosystems [3], and hence in our case the use of nanosystems 
with other shapes may increase circulation time and eventually enhance tumor accumulation. 
Besides this, GNRs exhibit strong surface plasmon band in the visible (~520 nm) and near 
infrared (~900 nm) regions corresponding to the transverse and longitudinal surface plasmon 
oscillations of free electrons, respectively. The interaction of incident infrared light with the 
GNRs produces ultimately localized heating, which can be used to trigger thermal damage 
locally. Because infrared light can penetrate deeply into tissues, photothermal therapy using 
GNRs as the sensitizing agent has been investigated in the recent years, both to induce local 
heating and to trigger drug release upon interaction with incident light [4-6]. 
In this chapter, as a third approach for the development of gold NP-based BNCT agents, we 
selected rod-shaped gold particles functionalized with PEG-thiol (to improve GNRs stability and 
prolong circulation time during in vivo biodistribution studies). As the boron source, we decided 
to incorporate the boron cluster [4.4]- (see chapter 3) on the GNRs surface via Au-S interaction. 
The resulting multifunctionalized GNRs were radiolabeled with 64Cu, a positron emitter with a 
half-life of 12.7 hours, to enable in vivo imaging using Positron Emission Tomography (PET). 
The radiolabel was incorporated on the surface of the GNR core via chemical reduction of 
64CuCl2 under mild reaction conditions. The presence of gold nanorods and boron atoms in the 
tumor tissue, as demonstrated in our in vivo experiments, should enable the application of 
simultaneous BNCT and photothermal therapy, with the consequent improved therapeutic 
efficacy.  




The specific objectives of this chapter are: 
5- To synthesize and characterize stable and biocompatible GNRs functionalized with PEG and 
COSAN. 
6- To perform radiolabeling studies for the incorporation of positron emitters in the core of the 
multifunctionalized GNRs. 
7- To perform in vitro studies (cytotoxicity and cell internalization studies) of 
multifunctionalized GNRs in different cell lines; namely, MKN45 gastric cell line and human 
dermal fibroblasts (HDFa) cell line. 
8- To evaluate pharmacokinetic properties of the novel multifunctionalized GNRs using positron 
emission tomography (PET) in a human gastrointestinal adenocarcinoma mouse model 
(MKN45 human cell line) after intravenous administration. 
5.3 Results and Discussion 
5.3.1 Synthesis and Characterization of GNR-mPEG@[4.4]- 
The approach that we followed for the preparation of boron-rich GNRs was similar to that used in 
previous chapters, this is, we used the same stabilising agent and the same boron cluster, [3,3’-
Co(1,2-C2B9H10)(8’-O-(CH2)5-SH-1’,2’-C2B9H11)]- ([4.4]-), which was synthesized following the 
method described in Chapter 3.  
In parallel, cetyltrimethylammonium bromide (CTAB)-stabilised GNRs (GNR-CTAB) were 
prepared following the seedless method [7]. The conditions were adjusted in order to achieve 
monodisperse GNRs with average dimensions (length × width) of 37 × 10 nm, in a one-pot 
reaction. In brief, HAuCl4 was added to CTAB solution and shaken for 1 min. To this solution, 
silver nitrate was added and shaken gently for 1 min. Hydrochloric acid was introduced to obtain 
a pH close to 2.0. After that, ascorbic acid was added under gentle stirring until the solution 
became clear. In the final step, ice-cold sodium borohydride was injected into the growth solution 
and allowed to react for 6 h. The growth solution was maintained at 27-30 °C in a water bath 
(Figure 5.1). The synthesized GNR-CTAB were centrifuged twice at 14500 rpm to remove the 
excess CTAB as well as other reagents, and re-dispersed in water.  




Figure 5.1. Schematic representation of the preparation of GNR-CTAB. 
The obtained GNR-CTAB were analysed by UV-Vis-NIR spectrophotometry, transmission 
electron microscopy (TEM) and dynamic light scattering (DLS). UV-Vis-NIR showed the 
longitudinal surface plasmon resonance (SPR) band centred at 811 nm (Figure 5.2a). TEM 
images showed uniform gold nanorods with sizes 37±3 × 10±1 nm (length × width; aspect ratio 
of 3.7) (Figure 5.2b). Zeta-potential values of +35±1 mV were obtained, as expected due to the 
positively charged CTAB surfactant bilayer [8] (Figure 5c). 
The biological application of GNRs requires the removal of CTAB surfactant bilayer due to its 
high toxicity and the poor colloidal stability in biological media [9]. Therefore, to increase the in 
vivo stability, biocompatibility and blood circulation half-life of GNRs, several GNRs surface 
modifications by ligand exchange with different polymers have been proposed [10-12]. Among 
the many different polymers and ligands, poly(ethylene glycol)thiol (PEG-SH) is one of the most 
commonly used in the modification of gold nanostructures. PEG polymers provide high degree of 
stability, low toxicity and high biocompatibility for GNRs and several PEGylated products have 
been approved by the FDA (Food and Drug Administration) for clinical use.  
 




Figure 5.1. UV-Vis-NIR absorption spectra (a); TEM (b) and Zeta potential (c) of GNR-CTAB. 
CTAB-protected GNRs were functionalized with PEG by reacting with methoxyPEG5k–SH for 
20–24 h in pure water based on previously reported protocols [11, 13]. In this work, mPEG-
stabilized GNRs (GNR-mPEG) were prepared by mixing GNR-CTAB solution with 5 kDa 
mPEG (PEG:Au molar ratio of 1.5) for 24 hours at room temperature in water (Figure 5.3).  
 
Figure 5.3. Schematic representation of the preparation of GNR-mPEG. 
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The functionalization of GNRs with mPEG–SH was much more complex than that of the citrate-
AuNPs because of a strong capping surfactant (CTAB) on the nanorods. In the case of spherical 
gold nanoparticles the citrate monolayer can be very easily replaced by the thiol group (reaction 
time 2 h); however, the double-layered CTAB on GNRs hinders the binding of PEG–SH to the 
GNR surface, leading to a slow loading speed of PEG–SH. After 24 h reaction, the synthesized 
GNR-mPEG were centrifuged twice at 14500 rpm to remove the excess PEG, and re-dispersed in 
water. The minimal bathochromic shift in the longitudinal SPR band from 800 to 819 nm (Figure 
5.4a) after replacement of CTAB by mPEG confirms the retention of structural and optical 
properties of the GNRs after modification. Replacement of positively charged CTAB with neutral 
PEG chains resulted in zeta potential values close to neutral (8±2 mV; Figure 5.4b). TEM images 
revealed the similar size and aspect ratio of GNRs before and after PEGylation (Figure 5.4c). 
 
 
Figure 5.4. UV-vis-NIR of GNR-CTAB and GNR-mPEG (a); Zeta potential (b) and TEM images (c) of 
GNR-mPEG. 
After successful functionalization of GNRs with mPEG-thiol, we next tackled the attachment of 
thiolated COSAN derivative ([4.4]-) on the GNR-mPEG surface. This was carried out by 
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incubation of GNR-mPEG solution and compound [4.4]- in ethanol under stirring for 2 h at room 
temperature (Figure 5.5).  
 
Figure 5.5. Preparation of GNR-mPEG@[4.4]- from GNR-mPEG. 
In order to evaluate the loading capacity of the boronated ligand into the GNRs, these were 
incubated with different amounts of [4.4]- (GNR/[4.4]- molar ratios: 12, 10, 8, 6, 4, 2, 1.5 and 
1.0). Upon surface modification of GNR-mPEG with different concentrations of [4.4]-, no tailing 
or broadening was observed in the normalised UV-vis spectra, indicating excellent stability of the 
synthesized GNRs (Figure 5.6). However, broadening of the longitudinal peak and increase in the 
intensity of the transversal absorption band indicate the instability of the functionalized GNRs for 
GNR/[4.4]- molar ratio 1.0 (blue line, Figure 5.6). Therefore, the GNR/[4.4]- molar ratio 1.5 was 
considered as optimal ratio to load the boron rich compound on GNR surface, as under these 
conditions we expected to obtain maximum concentration of boron on the NPs without affecting 
the stability and aggregation status of the nanorods.  
After purification by centrifugation and repeated washing, boron-rich GNRs (GNR-
mPEG@[4.4]-) were obtained. The size and aspect ratio remained the same as for GNR-mPEG 
(Figure 5.7a). While UV-Vis-NIR spectroscopy showed unchanged absorption maximum at 819 
nm (Figure 5.7b), a new absorption band appeared at 320 nm, related to the absorption by 
COSAN (314 nm), suggesting successful adsorption of the boron cluster on the surface of GNRs. 
The recorded shift of the zeta potential value, from 8±2 mV to -12±2 mV (Figure 5.7c), confirms 
the attachment of negatively charged cobalt-bis-dicarbollide complexes on the GNR surface.  
 




Figure 5.6. Normalised UV-Vis-NIR spectra of GNR-mPEG@[4.4]- with different GNR/[4.4]- molar 
ratios. 
 
Figure 5.7. a) Representative transmission electron micrograph (TEM) of GNR-CTAB (left),  GNR-
mPEG (middle) and GNR-mPEG@[4.4]- (right); b) UV-vis-NIR absorption spectra of GNR-CTAB (blue 
line), GNR-mPEG (red line), GNR-mPEG@[4.4]- (green line) and compound [4.4]- (yellow line); and c) 
Zeta-potential values measured for GNR-CTAB, GNR-mPEG and GNR-mPEG@[4.4]-. 
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As an additional structural evidence, the presence of COSAN on the surface was confirmed by 
scanning transmission electron microscopy (STEM) combined with energy-dispersive X-ray 
spectroscopy (EDXS). The energy bands in STEM-EDXS corresponding to cobalt and boron 
were observed, confirming the presence of [4.4]- on the surface of particles (Figure 5.8). 
 
 
Figure 5.8. a) STEM images of GNR-mPEG@[4.4]-; the areas analyzed with EDXS are delineated in 
blue; b) sum EDXS spectrum of the selected GNRs. 
Furthermore, X-ray photoelectron spectroscopy (XPS) analysis of GNRs-mPEG@[4.4]- showed a 
peak at 780.2 eV in the Co spectrum, corresponding to Co-B bonds, and peaks at 192.8 and 188.5 
eV, corresponding to B-O and C-B bonds, respectively (Figure 5.9) [14]. These results confirmed 
the presence of both cobalt and boron on the surface of the nanorods.  
In order to determine the loading capacity of the system, ICP-MS analysis were performed to 
measure the gold and boron content in the final GNR-mPEG@[4.4]- (GNR/[4.4]- molar ratio 1.5). 
The amount of [4.4]- was estimated to be 225 µg per mg of gold, which results in ca. 100 µg of 
boron/mg of gold.  




Figure 5.9. X-ray photoelectron spectroscopy (XPS) analysis of GNRs-mPEG@[4.4]- 
5.3.2 In vitro studies 
Cytotoxicity studies 
To evaluate the cell cytotoxicity of the multifunctional GNR-mPEG@[4.4]-, the MKN-45 gastric 
adenocarcinoma and human dermal fibroblasts (HDFa) cell lines were used as in vitro models. 
These cell lines were treated with 10, 20, 40, 60, 80, and 100 μM (gold concentration) of the 
GNRs for up to 72 hours prior to analysis using the MTT assay.  
The results (Figure 5.10) confirm that treatment of MKN-45 and HDFa cells with GNR-
mPEG@[4.4]- did not reduce the viability of the cells at any of the concentrations assayed, 
indicating negligible cytotoxicity in this range of concentrations.  




Figure 5.10. Cell viability in the presence of GNR-mPEG@[4.4]- for 24, 48 and 72 hours: a) MKN45 
gastric cell line and b) human dermal fibroblasts (HDFa); in both cases, cells were incubated with 
increasing concentrations of GNRs and cell viability was determined by the MTT assay. Data are shown 
as the mean ± standard deviation of three independent experiments. 
Cell internalization studies 
Incubation of nanoparticles with cells seeded on a surface [two-dimension (2D) cell culture] is 
the most common method to evaluate the cellular uptake of nanoparticles. The cellular uptake of 
multifunctionalized GNRs was investigated in MKN-45 cells (as these are the cells inoculated for 
the generation of the tumor model, vide infra) using live cell fluorescence microscopy. With that 
aim, a fluorophore needed to be incorporated on the NPs. To enable conjugation with a 
fluorophore, GNR-mPEG@[4.4]- were reacted with PEG-amine-thiol (5kDa) at room 
temperature for 2h, centrifuged at 14000 rpm for 10 min and washed two times with water. Then, 
the fluorophore Cy3-NHS ester dissolved in DMSO was added to amino-functionalized GNR-
mPEG@[4.4]- (pH 7.4-8.0) and stirred for 2h at room temperature, centrifuged at 14000 rpm for 
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10 min and washed two times with water. The fluorophore-labeled GNR-mPEG@[4.4]- were 
incubated with MKN-45 cells for 2 h. To enable co-localization between the GNR-mPEG@[4.4]- 
and the lysosomes, these were stained with Lysotracker-deep-red. Images were obtained using a 
live cell Axio Observer (Zeiss) fluorescence microscope and analyzed by the ZEN-ZEISS 
software, showing a clear co-localization between the GNR-mPEG@[4.4]- and the Lysosomes 
and therefore demonstrating internalization (Figure 5.11). 
 
 
Figure 5.11. Live cell fluorescence microscopy of GNRs after 2 h incubation. In green: GNR-
mPEG@[4.4]-, fluorophore-labeled with NHS-Cy3; in red: Lysosomes, stained with LysoTracker deep 
red; in blue: nucleus, stained with Hoechst33342. Merged signals of GNR-mPEG@[4.4]-, colocalizing 
with lysosomes appear in yellow. 
5.3.3. Radiolabeling of GNRs-mPEG@[4.4]- with 64Cu  
To introduce PET imaging capabilities to nanosystems, one of the most common way consists of 
attaching the radionuclide 64Cu via a metal chelator [15]. However, the possible detachment of 
the 64Cu atom by transchelation from the chelator complex could lead to a significant difference 
between the radionuclide signal and the distribution of GNRs. A few years ago, Sun et al. 
reported a straightforward, facile synthesis of 64Cu labeled gold nanomaterials for PET imaging 
guided therapy in a U87MG glioblastoma xenograft model [16]. Based on this protocol, 
multifunctional GNRs were labeled with 64Cu radionuclide. In brief, [64Cu]CuCl2 was reduced in 
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the presence of hydrazine (N2H4) on the surface of GNRs-mPEG@[4.4]- at room temperature for 
1 hour (Figure 5.12).  
 
Figure 5.12. Schematic representation of radiolabeling of GNRs-mPEG@[4.4]- with 64Cu. 
After 1h, the synthesized GNRs-mPEG@[4.4]- were challenged with ethylenediaminetetraacetic 
acid (EDTA, 10 mM in neutral 50 mM phosphate buffer, 5 μL) and centrifuged at 14000 rpm for 
10 min and washed two times with water. The radiochemical purity of [64Cu]GNRs-
mPEG@[4.4]- was monitored by using instant thin-layer chromatography (iTLC) paper (Agilent 
Technologies) with 20 mM citric acid and 60 mM EDTA/acetonitrile solution (9/1 v/v) as the 
stationary and mobile phases, respectively.  
 
Figure 5.13. Radiochemical purity of [64Cu]GNRs-mPEG@[4.4]- 
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Radiochemical yields close to 70% were achieved and radiochemical purity was > 98% (Figure 
5.13), as derived from the presence of one single peak in the chromatogram at the seeding 
position. Noteworthy, TEM images and UV-Vis-NIR spectra of GNRs-mPEG@[4.4]- (after 
radioactive decay) remained unaltered after incorporation of the 64Cu radiolabel on the gold core, 
confirming the suitability of labeling method to tackle in vivo experiments (Figure 5.14). 
 
Figure 5.14. TEM image (a) and UV-Vis-NIR spectra (b) of [64Cu]GNRs-mPEG@[4.4]- after complete 
radioactive decay). 
5.3.4. Radiochemical stability 
As mentioned in previous chapters, the stability of the radiolabel is paramount when performing 
in vivo experiments, because detachment of the radiolabel may lead to wrong interpretation of the 
imaging data. When radiometals are employed for radiolabeling, one of the most conclusive 
approaches to determine stability in vitro consists of incubating the labeled species in the 
presence of a chelator capable of sequestrating the radionuclide. Following this rationale, we 
investigated the radiochemical stability of [64Cu]GNRs-mPEG@[4.4]- by incubation in three 
different media at 37 °C: (i) Physiological saline solution containing EDTA as a chelator (0.9% 
NaCl + 2.5 mM EDTA); (ii) phosphate buffered saline containing EDTA (PBS + 2.5 mM 
EDTA); and (iii) mouse serum.  
The experiments confirmed the excellent stability of the radiolabel, as expected due to the 
incorporation on the gold core. Irrespective of the medium, >92% of the initial 64Cu remained 
attached to GNRs-mPEG@[4.4]- at 48 h of incubation (Figure 5.15), thereby proving that the 
labeled GNRs are sufficiently stable to proceed to in vivo experiments.  




Figure 5.15. Radiochemical stability of GNR-mPEG@[4.4]- at different incubation times in: 
physiological saline solution containing EDTA (0.9% NaCl + 2.5 mM EDTA); phosphate buffered saline 
containing EDTA (PBS + 2.5 mM EDTA); and mouse serum. 
5.3.5. In vivo studies 
Following the investigation of in vitro toxicity and cell internalization, we tackled the 
determination of the biodistribution of the labeled nanorods in a xenograft mouse model 
generated by subcutaneous administration of MKN-45 cells, using PET imaging in combination 
with computerized tomography (CT) (Figure 5.16).  
 
Figure 5.16. Schematic representation of in vivo analysis of [64Cu]GNR-mPEG@[4.4]- using PET-CT  
General biodistribution of the labeled GNRs and the accumulation in the tumor were determined 
by acquiring static PET images at different time points after administration of the labeled species 
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(1, 4, 24 and 48 hours; see Figure 5.17 for representative images). Volumes of interest (VOIs) 
were drawn in major organs and tumor tissue based on reconstructed CT images, and used to 
quantify PET images. The concentration of radioactivity in each region was determined as 
percentage of injected dose per cubic centimeter of tissue (%ID/cm3) (Figure 5.18a).  
 
a b c d
 
Figure 5.17. Representative PET images (coronal views) obtained at 1 (a), 4 (b), 24 (c), and 48 (d) hours 
after administration of [64Cu]GNR-mPEG@[4.4]- in mice bearing MKN-45 tumor. Maximum intensity 
projection (MIP) PET images were co-registered with representative CT coronal slices. The position of the 
tumor is indicated with white arrows. 
At t = 1 hour, high accumulation of radioactivity was observed in the heart (28.7±3.2 %ID/cm3), 
suggesting the presence of a significant amount of labeled GNRs in the blood pool. This value 
progressively decayed with time, to reach a value of 2.22±0.16 %ID/cm3 at t = 48 hours. A 
mono-exponential equation was fitted to the obtained values, to determine an estimated half-life 
of GNRs in blood of 1.4 hours (Figure 5.18d).  
High accumulation of GNRs was observed in liver at short times after administration (26.3±2.8 
%ID/cm3), as well as in the lungs (14.6±3.0 %ID/cm3) and spleen (13.7±1.8 %ID/cm3). In these 
organs, a progressive decrease of radioactivity concentration was observed over time, reaching 
values of 15.5±3.9 %ID/cm3, 0.96±0.5 %ID/cm3 and 4.3±3.4 %ID/cm3, respectively, at t = 48 
hours after administration. These results suggest moderate sequestration of the NPs by organs of 
the mononuclear phagocyte system (MPS). Lower accumulation in kidneys (i.e. 9.3±1.0 
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%ID/cm3), and no significant elimination via urine were observed, suggesting a very slow 
glomerular filtration rate, and hence confirming the stability of the label. A progressive decrease 
of the amount of GNRs found in liver and kidneys is important because this trend may reduce 
local side- or toxic effects in eventual long-term treatments. 
 
 
Figure 5.18. (a,b) Accumulation of [64Cu]GNR-mPEG@[4.4]- in different organs (a) and the tumor (b) at 
different time points after intravenous administration, as determined by PET imaging; (c) tumor-to-muscle 
ratios at different time points; (d) Time activity curve in blood; (e) correlation of results obtained by in 
vivo imaging and dissection/gamma counting. In all cases, values are expressed as mean ± standard 
deviation (n=4).  
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Noteworthy, the concentration of radioactivity in the tumor progressively increased with time 
(Figure 5.18b) to reach the maximum value at t = 24 hours (3.3±1.2 %ID/cm3) and slowly 
decreased afterwards (2.7±1.8 %ID/cm3 at t =48 hours). The tumor-to-muscle ratio showed a 
similar trend, reaching the maximum of 5.4±2.7 at t = 24 hours after administration (Figure 
5.18c).  
5.3.6. Ex vivo studies 
In vivo biodistribution results were confirmed by ex vivo gamma-counting experiments, 
conducted immediately after finalizing the last imaging session. Mice were sacrificed after 48 h 
time point, organs of interest were harvested and the amount of radioactivity in each organ was 
measured in an automated gamma-counter (Wallach Wizard, PerkinElmer, Waltham, MA, USA). 
As depicted in Figure 5.18e, a good correlation between in vivo and ex vivo results was achieved. 
Major differences were encountered in the lungs. This is somehow expected, as the values 
determined in vivo (using PET imaging) are expressed as %ID/cm3, because volumes of interest 
are delineated. However, values obtained ex vivo correspond to %ID/g, and hence in vivo and ex 
vivo data should match only when the density of the tissue investigated is close to 1. This is not 
the case for a breathing lung under physiological conditions, where the density is assumed to be 
close to 0.5 g/cm3 due to the presence of a large volume of air. 
Our results above assume that the GNRs are chemically and radiochemically stable over the 
whole duration of the study, this is, that the imaging results reflect the real accumulation of GNR-
mPEG@[4.4]- in different organs and tumor tissue. Despite the low elimination via urine suggest 
that the radiolabel does not detach from the NPs, it is not a proof of the chemical stability of the 
NPs.  
In order to prove that the presence of radioactivity in the tumor (as well as other organs) can be 
correlated with the actual concentration of nanoparticles (and boron), the concentration of boron 
and gold in selected organs (spleen, liver) as well as in the tumor were determined by ICP-MS 
(Figure 5.19). As it can be seen, a good correlation between results obtained by ICP-MS and in 
vivo imaging was achieved, confirming the stability of our functionalized GNRs and their 
capacity to reach the tumor. 




Figure 5.19. Amount of gold and boron in the spleen, the liver and the tumor at 48 hours after intravenous 
administration of GNR-mPEG@[4.4]-, as determined by ICP-MS and PET imaging. Values for PET 
imaging are obtained by multiplying the %ID/cm3 (values from Figure 5.18a) by the relative load of boron 
and gold in the nanosystems. 
Our biodistribution data are in good agreement with results reported in the literature. Although no 
examples of boron-rich GNRs have been reported, GNRs bearing other functionalities have been 
assayed in vivo. In one of the examples reported, non-targeted, PEG-stabilized GNRs were 
evaluated in a xenograft mouse model of breast cancer and maximum accumulation in the tumor 
was observed at 6–24 hours after administration, with values slightly above 5% ID/g. These 
uptake values could be significantly increased by covalently attaching a bombesin peptide to the 
GNRs. The authors also observed high accumulation in liver and kidneys  [17].  In a more recent 
work [18], slightly larger (93.4 nm in length, 24.8 nm in width; aspect ratio = 3.8) PEG-stabilized 
GNRs functionalized with  Arg-Gly-Asp- (RGD-) peptides were assayed in a mouse model of 
melanoma generated by subcutaneous inoculation of  𝛼v𝛽3-positive B16F10 mouse malignant 
melanoma cells. Maximum accumulation at 6 hours after administration was observed in liver 
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(26.51±4.93 %ID/g), lungs (7.07±0.25 %ID/g) and spleen (5.55±0.69 %ID/g), while 
accumulation in the tumor was 5.09±0.68 %ID/g and the tumor-to-muscle ratio was close to 10. 
We calculated the amount of boron accumulated in the tumor at different times after 
administration based on PET imaging results. Considering that: (i) the injected dose to the animal 
was 150 µg of GNR-mPEG@[4.4]- (amount of gold); (ii) GNRs contain 100µg boron per mg of 
gold; and (iii) the concentration of GNRs in the tumor at t = 24 hours after administration is 
3.3±1.2 %ID/cm3, the average concentration of boron in the tumor at t = 24 hours is 0.5 µg/cm3. 
This value is below the commonly accepted threshold to guarantee therapeutic efficacy in stand-
alone BNCT therapy. Higher values could however be easily achieved by administering higher or 
repeated doses.  
The values obtained with our nanosystems are significantly lower than those achieved with other 
nanocarriers. For example, the administration of carborane-appended water-soluble single-wall 
carbon nanotubes (administered dose per animal 4.6-10 mg) in a mouse model of mammary 
carcinoma resulted in boron concentration of almost 30 µg/cm3 [19]. In another, more recent 
work, boron-conjugated micelles with a boron load of 7.7 wt% were investigated in a mouse 
model of colon cancer, resulting in tumor uptake values close to 5 %ID/g in a time window 
between 24 and 48 hours after administration [20]. Intravenous administration of a dose of 15.6 
mg/kg to tumor-bearing mice was sufficient to retard growth significantly after neutron 
irradiation. 
It is worth mentioning that comparison of tumor accumulation of different boron-rich 
nanosystems should be performed with care, as different tumor models could lead to very 
different tumor accumulation values, even when experiments are performed at the same site and 
under identical experimental conditions. Our nanosystems, despite resulting in lower 
accumulation than that required to guarantee efficacious therapy, have the advantage of being 
capable to respond to light stimulus generating local heat, thus enabling combined BNCT and 
photothermal therapies.  
5.4. Summary and conclusions 
In this chapter, we developed a synthetic strategy for the preparation of GNRs simultaneously 
functionalized with mPEG5k-SH and a thiolated COSAN analogue (GNR-mPEG@[4.4]-). 
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Monidisperse and stable GNRs could be obtained with an aspect ratio of 3.7 (37±3 × 10±1 nm; 
length × width). The resulting GNRs showed good internalization capacity in MKN45 cells and 
low toxicity both in MKN45 and human dermal fibroblasts (HDFa). Treatment of the GNRs with 
64CuCl2 in the presence of a reducing agent enabled the incorporation of the positron emitter at 
the gold core, resulting in stable labeling in different media. In vivo experiments in a xenograft 
mouse model generated by inoculation of MKN45 cells showed significant accumulation of the 
GNR-mPEG@[4.4]- in the tumor and good tumor-to-muscle ratios at 24–48 hours after 
administration. Such multidecorated GNRs carry large amounts of boron, and hence bear the 
potential to become a valuable tool for the development of nanoparticle-based BNCT agents. 
This, together with the capability to absorb near infrared light, opens new avenues for their use in 
combined therapies (BNCT + photothermal therapy) 
5.5. Experimental section 
5.5.1. Reagents 
Cesium cobalt(III) bis(dicarbollide) (COSAN) (Katchem Ltd., Prague, Czech Republic), 
tetrahydropyran (sigma-Aldrich), hexadecyltrimethylammonium bromide (CTAB, Sigma), 
gold(III) chloride trihydrate (HAuCl4·3H2O, Aldrich), sodium borohydride (NaBH4, Aldrich), 
silver nitrate (AgNO3, Sigma-Aldrich), ascorbic acid (Sigma), potassium carbonate (K2CO3, 
Sigma-Aldrich), poly (ethylene glycol) methyl ether thiol (MW 5000, Nektor), Cy3-NHS 
(BroadPharm®), and hydrazine hydrate (50–60%) (Sigma-Aldrich) were used as purchased. All 
other reagents and anhydrous solvents, stored over 4 Å molecular sieves, were purchased from 
Aldrich Chemical Co. (Madrid, Spain) and used without further purification. HPLC grade 
solvents were purchased from Scharlab (Sentmenat, Barcelona, Spain). 64Cu2+ in 0.1 M HCl was 
produced at CIC biomaGUNE Radiochemistry facility using cyclotron via the 64Ni(p,n)64Cu 
nuclear reaction. 
For chemical reactions, experiments were carried out under a dry, oxygen-free dinitrogen 
atmosphere unless otherwise noted. Analytical thin layer chromatography (TLC) measurements 
were conducted with silica gel 60 F254 plates (Macherey-Nagel). 




The 1H-NMR (500 MHz), 13C-NMR (126 MHz) and 11B-NMR (160 MHz) spectra were recorded 
on a 500-MHz Avance III Bruker spectrometer. All NMR spectra were performed in deuterated 
solvents at 22 °C. The 11B-NMR shifts were referenced to external BF3·OEt2, while the 1H and 
13C-NMR shifts were referenced to SiMe4. Chemical shifts are reported in units of parts per 
million (ppm) downfield from the reference peak and all coupling constants are reported in Hertz 
(Hz).  
UPLC/ESI-MS analyses were performed using an AQUITY UPLC separation module coupled to 
LCT TOF Premier XE mass spectrometer (Waters, Manchester, UK). An Acquity BEH C18 
column (1.7 µm, 5 mm, 2.1 mm) was used as stationary phase. The elution buffers were A (water 
and 0.1% formic acid) and B (Methanol and 0.1% formic acid). The column was eluted with 
gradient: t=0 min, 95% A, 5% B; t=0.5 min, 95% A, 5% B; t=5.5 min, 25% A, 75% B; t=16 min, 
1% A, 99% B; t=20min, 1% A, 99% B. Total run was 20 min, injection volume was 5 µL and 
flow rate 300 µL/min. The detection was carried out in both, negative and positive ion mode, 
monitoring the most abundant isotope peaks from the mass spectra (M-H+) or (M+H+). 
Transmission electron microscopy (TEM) was performed using a JEOL JEM-1400 plus 
microscope (Jeol, Tokyo, Japan) working at 120 kV. The carbon film of copper grids (CF400-
Cu) was treated under air plasma in a glow discharge system (Emitech K100X, 40mA during 2 
min) just before sample preparation. For TEM examinations, a single drop (1 μL) of the NPs 
solution was placed onto a copper grid coated with a carbon film (Electron Microscopy 
Sciences). After 1 minute, the drop was removed with filter paper and the sample was incubated 
with 3 μL of uranyl acetate 0.5% (3 min). The drop was removed with filter paper and the grid 
placed on top of a drop of water twice and dried with a filter paper. Scanning transmission 
electron microscopy (STEM) images were taken in a JEOL JEM-2100F (200kV, HAADF 
detector, coupled with an EDXS-INCA Oxford system). Energy dispersive X-ray spectroscopy 
(EDXS) of selected areas was carried out for thirty minutes, in which the sample displacement 
was automatically corrected every two minutes. A clear grid region without particle presence was 
analysed to evaluate the presence of scattered signals coming from the detector, grid and 
equipment microscope composition (Copper, Silicon and Iron, among others). These non-
relevant signals were omitted (<0.1 keV) or asterisk-labeled in the spectrum.  
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XPS experiments were performed in a SPECS Sage HR 100 spectrometer with a non-
monochromatic X ray source (Aluminium Kα line of 1486.6 eV energy and 252 W), placed 
perpendicular to the analyser axis and calibrated using the 3d5/2 line of Ag with a full width at 
half maximum (FWHM) of 1.1 eV. The selected resolution for the spectra was 15 eV of Pass 
Energy and 0.15 eV/step. All measurements were made in an ultra-high vacuum (UHV) chamber 
at a pressure around 6×10-8 mbar. An electron flood gun was used for charge neutralisation. 
Gaussian Lorentzian functions were used for fittings (after a Shirley background correction) 
where the FWHM of all the peaks were constrained while the peak positions and areas were set 
free. Main C1s peak was used for charge reference and set at 284.8 eV. 
ICP-MS measurements were performed on a Thermo iCAP Q ICP-MS (Thermo Fisher Scientific 
GmbH, Bremen, Germany). An ASX-560 autosampler was coupled to the ICP-MS (CETAC 
Tech, Omaha, NE, USA). UV-Vis-NIR spectra were measured in an Agilent 8453 UV-Vis-NIR 
diode-array spectrophotometer. ξ-potential measurements were performed using a Malvern 
Zetasizer Nano ZS system (Malvern Instruments, Malvern, UK). Radio-thin layer 
chromatography (radio-TLC) was performed using iTLC-SG chromatography paper (Agilent 
Technologies, CA, USA) and 20 mM citric acid + 60 mM EDTA/acetonitrile solution (9/1 v/v) as 
the stationary and mobile phases, respectively. TLC plates were analyzed using a TLC-reader 
(MiniGITA, Raytest). 
Cell observer microscopy experiments were carried out using a Zeiss Axio Observer 
Fluorescence microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and 
analyzed by ZEN2012-ZEISS. 
Confocal cell microscopy experiments were carried out using a Zeiss 880 Confocal Fluorescence 
microscope using Ibidi clear bottomed µ-slide 8-well microscopy plates and analyzed by 
ZEN2012-ZEISS. 
5.5.3. Chemistry 
Synthesis of GNRs using seedless growth method 
Gold Nanorods (GNRs) were synthesized following a seedless growth method. HAuCl4 (100 µL, 
0.05 M) was added to 10.0 mL of cetyltrimethylammonium bromide (CTAB; 0.1 M) and shaken. 
Following this, AgNO3 (250 µL, 4.0 mM) was added, and the solution was gently shaken. HCl 
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(12.0 µL, 37 wt%) was introduced to obtain a pH close to 1.0 followed by addition of 70 µL of 
ascorbic acid (78.8 mM) under gentle stirring until the solution became clear. In the final step, 
ice-cold NaBH4 (10 µL, 0.01 M) was injected into the growth solution and allowed to react for 6 
h. The growth solution was maintained at 27 °C in a water bath. The synthesized GNRs were 
centrifuged twice at 10.000×g to remove the excess CTAB as well as other reagents, and re-
dispersed in water. 
Synthesis of PEG-modified GNRs 
A GNR solution as prepared above was centrifuged at 10.000×g for 10 min, decanted, and 
resuspended in water to remove excess CTAB. A thiol-terminated PEG solution (300 µL, 10 
mM, Nektor, MW ca. 5000, mPEG-SH) was added to the centrifuged GNR solution (2 mL; 1mM 
Au). The mixed solution was stirred for 24 hours at room temperature, and centrifuged twice at 
10.000×g for 10 min, decanted, and re-suspended in water to remove excess PEG reagent. 
Synthesis of PEG-stabilized, COSAN-functionalized GNRs 
To the PEG-modified GNRs (2 mL; 1 mM Au), 150 μL of a fresh solution of COSAN-SH [4.4]- 
in ethanol (3 mg/mL) were quickly added and stirring was maintained for 2 hours. The resulting 
NPs were centrifuged at 8.000×g for 20 min and resuspended in ultrapure water three times to 
remove excess COSAN-SH reagent, and re-dispersed in 1.0 mL ultrapure water.  
Synthesis of 64Cu-Integrated GNR-mPEG-COSAN 
64CuCl2 produced by proton irradiation of 64Ni as previously described [21], was diluted into 0.4 
M ammonium acetate buffer (NH4Ac, pH 5.5). A 500 μCi 64Cu solution was then added dropwise 
into the mPEG-stabilized, COSAN-functionalized GNRs solution (Au Concentration=250 
μg/mL). After stirring for 5 min, 3 μmol of N2H4 was added, and the solution was allowed to 
react at room temperature for 1 hour before it was washed by centrifugation to remove the excess 
reagents as well as the unreacted 64Cu. The labeling efficiency was calculated based on radiation 
dosimeter readings before and after purification. The labeling efficiency was determined by using 
instant thin-layer chromatography (ITLC) plates with 20 mM citric acid and 60 mM 
EDTA/acetonitrile solution (9/1 v/v) as an eluent.  
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Synthesis of fluorophore labeled PEG-stabilized, COSAN-functionalized GNRs 
The synthesis was performed as described previously with the difference of using 20 % PEG-
amine and 80 % PEG-methoxy to enable labeling with the fluorophore Cyanine3-NHS. Therefore 
200 µL of functionalized AuNP (1 mg/mL for rods and medium in MQ water) were adjusted in 
pH to 8.6-8.9 and 5 µL Cy3-NHS (1 mg/mL in DMSO) were added. After 1 h incubation at room 
temperature, the resulting NPs were centrifuged at 8.000×g for 20 min and resuspended in 
ultrapure water. The labeling was confirmed by UV-VIS spectrophotometry. 
5.5.4. In vitro studies 
Cytotoxicity studies 
To determine cell viability, MKN45 human gastric cancer cells and human dermal healthy 
fibroblasts (HDFa) cells were incubated with the GNRs over 24, 48 and 72 hours. Cells were 
seeded (3×104 cells/well, 100 μL/well, 96-well plate), allowed to adhere overnight in complete 
media (10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin in RPMI 1640 medium 
for MKN45 cells and DMEM medium for HDFa cells) and maintained in a humid atmosphere at 
37°C and 5% CO2. Then, media was removed and cells were left untreated (blank) or incubated 
with the GNR-containing formulations, diluted accordingly in media. The experiments were 
performed in triplicates. After the desired time, cell supernatant was removed and 100 μL/well of 
MTT reagent (Roche), diluted in the corresponding media to the final concentration of 0.25 
mg/mL, was added. After 1 hour incubation at 37°C and 5% CO2, the excess reagent was 
removed and formazan crystals were solubilized by adding 200 μL of DMSO per well. The 
optical density of each well was measured in a TECAN Genios Pro 96/384 microplate reader at 
550 nm. Data was represented as the percentage of cell survival compared to control wells. 
Cell internalization studies 
MKN45 cells were seeded in an ‘Ibidi’ µ-slide 8-well-plate (20 000 cells/well in 0.3 mL) and 
incubated over night to adhere (37 °C, 5% CO2, humid atmosphere). The media was removed and 
0.1 mL Hoechst 33342 (1 µg/mL in media) added to stain the nucleus. After 10 min incubation 
(37 °C, 5% CO2, humid atmosphere) 0.1 mL LysoTracker deep red (1 µg/mL in media) was 
added to stain the lysosomes. After 20 min incubation (37 °C, 5% CO2, humid atmosphere) 
media was removed and 0.3 mL of Cy3-labeled AuNP (20 µg/mL in medium) added. After 2 h 
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incubation (37 °C, 5% CO2, humid atmosphere) the media was removed and replaced with fresh 
media. The images were taken with a Cell Axio Observer Fluorescence Microscope. Controls of 
single staining for each fluorophore were included. Images were analyzed by ZEN-ZEISS 
software. 
5.5.5. In vivo experiments 
Animals 
The animals were maintained and handled in accordance with the Guidelines for Accommodation 
and Care of Animals (European Convention for Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes) and internal guidelines. Experimental procedures 
were approved by the ethical committee and local authorities. All animals were housed in 
ventilate cages and fed on standard diet ad libitum. 
MKN45 mouse tumor model development 
In order to study the biodistribution of the GNRs in tumor-bearing mice, Rj:NMRI-Foxn1nu/nu 
female mice (7-8 weeks old, Janvier) were subcutaneously inoculated with 2×106 MKN45 tumor 
cells in the right back. Prior to each inoculation, cells were diluted in sterile PBS:Matrigel (1:1) 
and  mycoplasma test (Lonza) was carried out to ensure that cells were not contaminated. Tumors 
were measured every 2–3 days with a digital caliper and volumes were calculated as V (mm3) = 
[(short diameter)2 x (long diameter)]/2. Biodistribution studies were carried out when tumor 
volume was approximately 200–300 mm3 (~15 days after tumor inoculation).  
Biodistribution studies 
PET studies with 64Cu-labeled multifunctionalized GNRs were carried out in MKN45 tumor-
bearing mice (n=4 per compound) using an eXplore Vista-CT small animal PET-CT system (GE 
Healthcare). Anesthesia was induced with 3% isoflurane and maintained by 1.5 to 2% of 
isoflurane in 100% O2. For intravenous administration of the radiotracer, the tail vein was 
catheterized with a 24-gauge catheter and the labeled NPs (ca. 3–10 MBq) were injected. PET 
images were analyzed using PMOD image analysis software (PMOD Technologies Ltd, Zürich, 
Switzerland). Volumes of interest (VOIs) were manually drawn in lungs, liver, heart, kidneys, 
spleen, brain, stomach, tumor and bladder using CT images as anatomical reference. VOIs were 
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then transferred to the PET images and time activity curves (decay corrected) were obtained for 
each organ as cps/cm3. Curves were transformed into real activity (Bq/cm3) curves. Injected dose 
normalization was finally applied to data to get time activity curves as percentage of injected 
dose per cm3 of tissue (%ID/cm3).  
Ex vivo studies 
The mice were sacrificed at 48 hours post injection, after the last imaging session. Organs of 
interest were collected and weighed, and the radioactivity was measured in a well gamma-counter 
(Wallach Wizard, PerkinElmer, Waltham, MA, USA). The uptake of 64Cu in the various organs 
was calculated as a percentage of the injected dose per gram of tissue (%ID/g) according to the 
prepared standards. The weighed organs (liver, spleen and tumor) were then immersed in digest 
solution (HNO3/HCl = 1:1) with a volume of 5 mL. The dispersions were heated to boiling until 
organs were completely dissolved. 1 mL of H2O2 was then added into the solution, and heating 
continued until the solution became clear and transparent. The solution was then cooled to room 
temperature, diluted by 2% HNO3 to 10 mL, and subsequently analyzed by ICP to determine the 
concentration of Au and B in each sample. 
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Chapter 6: Conclusions and future directions 
6.1. General conclusions 
1. Four gold-based, water-soluble, biocompatible and shape and size-tuned nanosystems, 
stabilized with polyethylene glycol and functionalized with the boron-rich anion cobalt 
bis(dicarbollide) (COSAN) could be successfully synthesized and characterized for their 
evaluation as drug candidates in the context of boron neutron capture therapy (BNCT).   
2. The nanosystems showed low In vitro cytotoxicity and good cell internalization capacity in 
different cell lines.  
3. The nanosystems could be efficiently radiolabeled with different positron emitters, namely 
iodine-124 and copper-64, enabling the in vivo monitoring using positron emission 
tomography (PET) imaging.  
4. Incorporation of the positron emitter iodine-124 both at the core and the shell of spherical 
gold nanoparticles with core size 18-21 nm and subsequent investigation using PET imaging 
in a xenograft mouse model of human fibrosarcoma, confirmed in vivo stability of the 
nanosystems, high accumulation in the organs of the mononuclear phagocytic system (MPS) 
and low accumulation in the tumor. 
5. Incorporation of the positron emitter copper-64 at the core of spherical gold nanoparticles 
with core size 9-11 nm and subsequent investigation using PET imaging in a xenograft mouse 
model of human gastrointestinal cancer, showed significant accumulation in the organs of the 
MPS and low accumulation in the tumor. Reduction of the core size of the spherical particles 
to 3-4 nm in diameter resulted in a higher bioavailability and increased accumulation in the 
tumor, with values of 5.3±1.3 %ID/cm3 at 24 hours after intravenous administration. These 
results were confirmed by ex vivo analysis using Inductively Coupled Plasma-Mass 
Spectrometry (ICP-MS).  
6. Incorporation of the positron emitter copper-64 at the core of gold nanorods with core size 
37±3 × 10±1 nm (length × width; aspect ratio of 3.7) and subsequent investigation using PET 
imaging in a xenograft mouse model of human gastrointestinal cancer, showed accumulation 
in the organs of the MPS and significant accumulation in the tumor, with values of 3.3±1.2 
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%ID/cm3 at 24 hours after administration. These results, which were confirmed by ex vivo 
analysis using ICP-MS, suggest the potential use of the nanosystems as boron carriers for 
BNCT and sensitizers for photothermal therapy.  
6.2. Future directions 
The work conducted in this PhD thesis has demonstrated that stable and biocompatible gold 
nanosystems functionalized with boron-rich compounds can be prepared, characterized and 
radiolabeled for the subsequent evaluation using in vivo positron emission tomography imaging. 
Despite the accumulation of boron in the tumor was not sufficient to guarantee therapeutic 
efficacy, the work conducted here may represent the first step towards the development of gold-
based BNCT agents.  
From the work reported, it is clear that size and shape tuning of the core of the nanosystems has a 
clear effect on the biodistribution and tumor accumulation. Hence, future work should tackle the 
investigation of other particle sizes, stabilizing agents and core-shapes, aiming at maximizing the 
boron content in the nanosystems and the accumulation of the nanosystems in the tumor. Also, 
the results obtained in chapter 5 related to the application of boron-rich gold nanorods, open new 
avenues for the preparation of nanosystems suitable for combined therapies. Hence, the use of 
gold nanosystems with favorable plasmonic properties, such as nanostars, is worth to be 
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